
Amended Safety Assessment of Triglycerides as Used in Cosmetics

Status: Final Amended Report
Release Date: February 14, 2018
Panel Meeting Date: December 4-5, 2017

The 2017 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Monice M. Fiume, Senior Director.

ABSTRACT

The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) assessed the safety of 51 triglycerides; 25 of these ingredients were previously reviewed by the Panel, and 26 are reviewed herein for the first time. The majority of the ingredients named in this assessment have several functions, with most reported to function as skin conditioning agents (occlusive or emollient) and/or viscosity increasing agents in cosmetics; some are also reported to function as a fragrance or solvent. The Panel reviewed relevant new data, including frequency and concentration of use, and considered the data from previous CIR reports. The Panel concluded the 51 triglycerides reviewed in this report are safe in cosmetics in the present practices of use and concentration described in this safety assessment.

INTRODUCTION

The Panel published the Final Report on the Safety Assessment of Trihydroxystearin in 2000.¹ Based on the available animal and clinical data, which included summary data from the CIR safety assessments of Hydroxystearic Acid and Glyceryl Stearate and Glyceryl Stearate SE, the Panel concluded that Trihydroxystearin is safe as used in cosmetics. In 2015, the Panel re-evaluated the safety of Hydroxystearic Acid and Glyceryl Stearate and Glyceryl Stearate SE, reaffirming that Hydroxystearic Acid is safe as a cosmetic ingredient in the present practices of use and concluding that Glyceryl Stearate and Glyceryl Stearate SE are safe in the present practices of use and concentration.² (In 1982, the conclusion issued for Glyceryl Stearate and Glyceryl Stearate SE was safe for topical application to humans.³)

The Panel issued two additional reports on related ingredients. In 2001, the Final Report on the Safety Assessment of Trilaurin and 22 additional glyceryl triesters was published,⁴ and in 1980, the Final Report of the Safety Assessment for Caprylic/Capric Triglyceride was published.⁵ In both safety assessments, the Panel reached the conclusion that the ingredients are safe as used in cosmetics. (In 2003, the Panel reaffirmed that conclusion for Caprylic/Capric Triglyceride.⁶) The 25 ingredients reviewed in the three reports are now included in this re-review:

Caprylic/Capric Triglyceride	Triheptanoin	Trioctanoin (now, Triethylhexanoin)
Glyceryl Stearate Diacetate	Triheptylundecanoin	Triolein
Glyceryl Triacetyl Hydroxystearate	Trihydroxystearin	Tripalmitin
Glyceryl Triacetyl Ricinoleate	Triisononanoin	Tripalmitolein
Triarachidin	Triisopalmitin	Triricinolein
Tribehenin	Triisostearin	Tristearin
Tricaprin	Trilaurin	Triundecanoin
Tricaprylin	Trilinolein	
Trierucin	Trimyristin	

In accordance with its procedures, the CIR evaluates the conclusions of previously-issued reports every 15 years, and it has been at least 15 years since these assessments have been issued. Because each report was reviewed 15+ years ago and they all comprise triglycerides, i.e., fatty acid triesters of glycerin, and because the collection of these ingredients in one report enables the assembly of reinforcing and complementary test data, the Panel determined these reports should be re-reviewed together in one document; this family is referred to as the triglycerides.

Also included in this assessment are 26 triglycerides named in the web-based *International Cosmetic Ingredient Dictionary and Handbook (Dictionary)* that have not been reviewed:

Acetic/Linoleic/Palmitic Triglyceride	Docosahexenoic/Docosapentenoic/Oleic/Palmitic Triglyceride
C8-12 Acid Triglyceride	Glyceryl Tri-Hydrogenated Rosinate
C12-18 Acid Triglyceride	Glyceryl Tripalmitate/Palm Kernelate/Oliveate/Macadamate/Rapeseedate
C18-36 Acid Triglyceride	Hydrogenated C12-18 Triglycerides
Capric/Lauric/Myristic/Oleic Triglyceride	Isomerized Safflower Glycerides
Caprylic/Capric/Lauric Triglyceride	Jobba Oil/Caprylic/Capric Triglyceride Esters
Caprylic/Capric/Linoleic Triglyceride	Lauric/Palmitic/Oleic Triglyceride
Caprylic/Capric/Myristic/Stearic Triglyceride	Oleic/Linoleic Triglyceride
Caprylic/Capric/Palmitic/Stearic Triglyceride	Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride
Caprylic/Capric/Stearic Triglyceride	Palmitic/Stearic Triglyceride
C10-40 Isoalkyl Acid Triglyceride	Ricinoleic/Caproic/Caprylic/Capric Triglyceride
Cod Liver/Mink/Tallow Triglyceride	Trilinolenin
C10-18 Triglycerides	Tripelargonin

A consolidated list of the 51 ingredients included in this review is provided in [Table 1](#).

According to the *Dictionary*, the majority of the ingredients named in this assessment have several functions, with most reported to function as skin conditioning agents (occlusive or emollient) and/or viscosity increasing agents in cosmetics; some are also reported to function as a fragrance or solvent.⁷ An exception is Glyceryl Tri-Hydrogenated Rosinate, which is only reported to function as a surfactant – emulsifying agent. A reported function of Docosahexenoic/Docosapentenoic/

Oleic/Palmitic Triglyceride is skin bleaching agent; skin bleaching agent is not a cosmetic function, and therefore use in that manner is not being assessed in this report. A complete listing of all the functions for each ingredient is given in [Table 2](#).

This safety assessment includes relevant published and unpublished data that are available for each endpoint that is evaluated. Published data are identified by conducting an exhaustive search of the world's literature. A listing of the search engines and websites that are used and the sources that are typically explored, as well as the endpoints that CIR typically evaluates, is provided on the CIR website (<http://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and-websites>; <http://www.cir-safety.org/supplementaldoc/cir-report-format-outline>). Unpublished data are provided by the cosmetics industry, as well as by other interested parties.

Excerpts from the summaries of the reports on the previously reviewed ingredients (as provided in those reports) are disseminated throughout the text of this re-review document, as appropriate, and are identified by *italicized text*. (This information is not included in the tables or the summary section.) For complete and detailed information, please refer to the original documents, which are available on the CIR website (<http://www.cir-safety.org/ingredients>). Additionally, the Discussions from the Trihydroxystearin (2000) and Trilaurin (2001) assessments are also included in this document.

The triglycerides all share a glycerin core. The Panel evaluated the safety of glycerin as used in cosmetics in 2014, concluding that glycerin is safe in cosmetics in the present practices of use and concentration described in the safety assessment.⁸ Additionally, the Panel reviewed the safety of 44 monoglyceryl monoesters in 2015, concluding that those ingredients are safe in the present practices of use and concentration,² and of a group of diglycerides in 2007, concluding this family of ingredients is safe in the present practices of use and concentration provided the content of 1,2-diester is not high enough to induce epidermal hyperplasia.⁹ Many of the acid components and related glyceryl esters of these triglycerides have also been reviewed by CIR. A listing of those that have been reviewed, and the associated conclusions, is provided in [Table 3](#).

Finally, much of the new data included in this safety assessment was found on the European Chemicals Agency (ECHA) website.¹⁰ Please note that the ECHA website provides summaries of information generated by industry, and it is those summary data that are reported in this safety assessment when ECHA is cited.

CHEMISTRY

Definition and Structure

The definitions and structures of the ingredients included in this triglyceride group are provided in [Table 2](#) and are presented in order of increasing chain length, subdivided by chain type. (Toxicity data are presented in the same order.)

Each of the ingredients in this report is a triglyceride; triglycerides are the fatty acid triesters of glycerin. Subsequently, each of the ingredient structures in this report contains a glycerin core, tri-substituted with fatty acid residues.




Figure 1. Triglycerides, wherein each “RC(O)-“ is a fatty acid residue

For example, Tricaprylin is the triester of caprylic acid with glycerin.




Figure 2. Tricaprylin (the triester of **caprylic acid** with glycerin)

Physical and Chemical Properties

Triglycerides are hydrophobic materials that range from oils, at the lowest molecular weights/shortest chain-lengths, to waxy solids, at the highest molecular weights/longest chain-lengths. Physical and chemical properties are presented in [Table 4](#).

Methods of Manufacture

One method of production of Trihydroxystearin involves the hydrogenation of castor oil, in the presence of the reagent nickel, at a temperature of 200°C. Another method of production is the reduction of triricinolein.¹

Trilaurin may be produced by reacting glycerin with lauric acid or glycerin with lauroyl chloride (reagent: pyridine or quinoline).⁴ The reaction of lauric acid with glycerin is another method of production. Triolein may be prepared by the esterification of oleic acid. Tripalmitin can be prepared from glycerin and palmitic acid in the presence of either Twitchell reagent or trifluoroacetic anhydride. Tristearin may be prepared from stearic acid and glycerin in the presence of Al₂O₃. Triundecanoin is produced by esterification of undecanoic acid and glycerin. The undecanoic acid is produced from castor oil, which is hydrolyzed to fatty acids and subjected to thermal degradation and fractionation. The resulting undecenoic acid is transformed to undecanoic acid and reesterified to the glycerin moiety. Deodorization, the final step, is accomplished using steam to remove components that give rise to unwanted flavors and odors.

Caprylic/Capric Triglyceride is manufactured by hydrolyzing coconut oil, removing the free glycerin, and separating the medium chain length fatty acids by fractional distillation.⁵ The acids are then blended in the proper ratio and re-esterified with glycerin.

Triglycerides (general)

Some of the triglycerides are produced synthetically via classical Fischer type esterification methods (i.e., reaction of carboxylic acids with glycerin to produce carboxylic esters), although the reaction may be promoted by acid or base catalysis, or by the use of an acid chloride. However, some of these ingredients may be natural sourced and produced by transesterification (i.e., exchange of acid moieties to create a different ester product). For example, the triglycerides in natural oils can be reacted with intended length fatty acids to produce new triglycerides.

The following are method of manufacture schemes for Caprylic/Capric Triglyceride (medium-chain triglycerides (MCT); terminology used in a FDA foods Generally Recognized as Safe (GRAS) notification, defined as triglycerides with alkyl chain lengths from 8 to 10 carbons long) ([Figure 3](#))¹¹ and medium- and long-chain triacylglycerol (MLCT)-oil (terminology used in a FDA foods GRAS notification, defined as triglycerides with alkyl chain lengths from 8 to 24 carbons long) ([Figure 4](#)):¹²




Figure 3. Caprylic/Capric Triglyceride (MCT) production scheme




Figure 4. MLCT production scheme

Impurities

Triundecanoin contains no impurities or residues of catalysts or solvents.⁴ 1,4-Dioxane, ethylene oxide, free amines, and nitrosamines are not added or formed during the production process. Furthermore, volatile compounds are effectively removed, by the deodorization process, below detection limits (0.1 ppm). The deodorization process also has removed any organochlorine or organophosphorus pesticides that may be present in the crude oil used in the production process. It is also important to note that the total content of polycyclic aromatic hydrocarbons (PAHs), if present in the crude oil, is reduced below 10 ppb. Additionally, aflatoxins, if present in the raw materials, are reduced below detection limits (0.5 ppb) by neutralization and bleaching.

The only known impurities of Caprylic/Capric Triglyceride are approximately 300 ppm free fatty acids and as much as 0.2% glycerin.⁵ The relatively low iodine number 5, which is determined in an arbitrary but standard method, indicates very little unsaturated material present.

USE

Cosmetic

The safety of the cosmetic ingredients addressed in this safety assessment is evaluated based on data received from the FDA and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in the FDA VCRP database. Use concentration data are submitted by the cosmetic industry in response to a survey, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category.

According to information from the VCRP and that received from the Council, 30 ingredients assessed in this report are in use. Caprylic/Capric Triglyceride has the highest frequency of use; according to 2017 VCRP data, it is used in 6000 cosmetic formulations, with uses reported for all exposure types.¹³ Tribehenin has the next highest frequency of use, with 723 reported uses, followed by Triethylhexanoin, with 601 reported uses. (Table 5; Table 6)

Use concentration survey data were collected in 2015/2016 (and updated in 2017) for some of ingredients,¹⁴ and in 2017 for the remaining ingredients.¹⁵ The results indicate that Triethylhexanoin has the highest maximum use concentration in leave-on formulations, with concentrations of 100% reported for face and neck formulations and 63% in lipstick formulations (Table 5). Caprylic/Capric Triglyceride has the next highest maximum use concentration in leave-ons, with concentrations of 95.6% in face and neck products.

Approximately half of the ingredients included in this safety assessment have been reviewed previously by the Panel. The frequency and maximum concentrations of use for the majority of these ingredients has increased when compared to the previous review. The most remarkable increase is in the frequency of use of Caprylic/Capric Triglyceride; in 2003, this ingredient was reported to be used in 763 formulations and in 2017, it is reported to be used in 6000 formulations.^{5,6} Concentrations of use have also increased.^{6,14} In 2003, the maximum leave-on concentration of use for this ingredients was 84%, it is now reported to 95.6%; maximum concentrations of use increased for eye area, non-coloring hair, hair coloring, nail, and baby product formulations. The increase in baby products was quite notable, increasing from 0.8% to 52%.

The 21 triglycerides not currently reported to be in use, according to VCRP and concentration of use survey data, are listed in Table 7.

In some cases, reports of use were received from the VCRP, but no concentration of use data were provided. For example, Trilinolenin is reported to be used in 2 formulations,¹⁶ but no use concentration data were provided. In other cases, no uses were reported to the VCRP, but a maximum use concentration was provided in the industry survey. For example,

Caprylic/Capric/Linoleic Triglyceride was not reported in the VCRP database to be in use, but the industry survey indicated that it is used at concentrations up to 52.1% in body and hand product formulations.¹⁵ It should be presumed that Caprylic/Capric/Linoleic Triglyceride is used in at least one cosmetic formulation for each category for which it is reported to be used.

Some of the triglycerides are used at relatively high concentrations in products that can be used near the eye, can possibly be ingested, or come in contact with mucous membranes; for example, Caprylic/Capric Triglyceride is used at up to 83.3% in eye lotions, and Triethylhexanoin is used at up to 63% in lipstick formulations. Additionally, some of these ingredients are used in cosmetic sprays and powders and could possibly be inhaled; for example, Caprylic/Capric Triglyceride and Triethylhexanoin are reported to be used at maximum concentrations of 38% in spray body and hand formulations and 36% in perfumes, respectively, and 16% and 14.7%, respectively, in face powders. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters >10 µm, with propellant sprays yielding a greater fraction of droplets/particles <10 µm compared with pump sprays.^{17,18} Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and thoracic regions of the respiratory tract and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount.^{19,20} Conservative estimates of inhalation exposures to respirable particles during the use of loose-powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.²¹⁻²³ Caprylic/Capric Triglyceride is used at up to 0.99% in spray deodorant formulations. There is some evidence indicating that deodorant spray products can release substantially larger fractions of particulates having aerodynamic equivalent diameters in the range considered to be respirable.²⁰ However, the information is not sufficient to determine whether significantly greater lung exposures result from the use of deodorant sprays, compared to other cosmetic sprays.

All the triglycerides described in this safety assessment (and listed in the *Dictionary*) are not restricted from use in any way under the rules governing cosmetic products in the European Union (EU).²⁴ In Australia, Triethylhexanoin cannot be classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances*.²⁵

Non-Cosmetic

*Trihydroxystearin has been used as a thickening agent for peanut butter.*¹ FDA has listed the following indirect food additive uses in the Code of Federal Regulations (CFR): components of adhesives (21CFR 175.105), components of resinous and polymeric coatings (21 CFR 175.300), components of paper and paperboard in contact with aqueous and fatty foods (21 CFR 176.170), components of paper and paperboard in contact with dry food (21 CFR 176.180), defoaming agents used in the manufacture of paper and paperboard (21 CFR 176.210), cellophane (21CFR 177.1200), closures with sealing gaskets for food containers (21 CFR 177.1210), polyester resins cross-linked (21 CFR 177.2420), and textiles and textile fibers (21 CFR 177.2800).

*Trihydroxystearin is among the inert ingredients that are exempt from the requirement of a tolerance under the Federal Food, Drug, and Cosmetic Act when used in pesticide formulations that are applied to crops.*¹

*Trilaurin has been detected in pharmaceutical excipients.*⁴ *Tricaprylin has been used as an energy source for burn patients and for patients having difficulty digesting long-chain fatty acids. Tristearin has been approved for use as a direct food additive (21 CFR 172.811). Additionally, the following glyceryl triesters have been approved for use as components of articles intended for use in producing, manufacturing, packing, processing, preparing, treating, packaging, transporting, or holding food (i.e., use as indirect food additives): Trilaurin, Trimyristin, Triolein, Tripalmitin, Tristearin (21 CFR 177.2800), and Glyceryl Triacetyl Hydroxystearate (21 CFR 178.3505).*

*The following non-cosmetic uses of Tristearin have been reported: soap, candles, candies, adhesive pastes, metal polishes, waterproofing paper, textile sizing, leather stuffing, and manufacture of stearic acid.*⁴

*Letters issued by the FDA have attested to the safety of Caprylic/Capric Triglyceride when used as a food additive.*⁵ *In addition, it has also been marketed for consumption since 1962 as a nutritional supplement and blood lipid lowering agent. It has also been suggested for use in enteric drugs and rectal suppositories and as a vehicle for topically applied pharmaceuticals.*

C10-18 Triglycerides is approved for use as direct multipurpose food additives (21CFR172.861).

Caprylic/Capric Triglyceride and Triglycerides (general)

The FDA received a GRAS notification request for triglycerides (C8-C24) for use as a food ingredient, such that the total daily consumption would not exceed 31 g/day.¹² The FDA responded that the tailored triglycerides ingredient (12% Caprylic/Capric Triglyceride) is GRAS under the intended conditions of use as an oil in home cooking, salad dressings, vegetable-oil spreads, and frozen dinners (including meat and poultry).²⁶ The agency has not, however, made its own determination regarding the GRAS status of the subject use of the tailored triglycerides (12% Caprylic/Capric Triglyceride) ingredient.

Caprylic/Capric Triglyceride, is a component of a homogenous lipid emulsion approved for intravenous (i.v.) infusions indicated for use in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.²⁷ The lipid content of the infusion is 0.20 g/ml, and comprises a

mixture of soybean oil, Caprylic/Capric Triglyceride, olive oil, and fish oil; recommended dosing is 1 to 2 g/kg/day, not exceeding 2.5 g/kg/day.

TOXICOKINETIC STUDIES

Dermal Penetration

In mice and guinea pigs, little skin penetration was observed.⁴ In the mice, ¹⁴C-Triolein (undiluted or in hydrophilic ointment) did not penetrate into the body organs of mice, and the oil remained localized at the application site at 48 h post application.

Penetration Enhancement

Tricaprylin enhanced the skin penetration of drugs in vivo (Wistar rats) and in vitro (hairless mice).⁴ The skin penetration enhancement of drugs in the presence of Triolein has been reported.

Absorption, Distribution, Metabolism, and Excretion

Metabolism data indicate that most triglycerides (or glyceryl triesters) are split into monoglycerides, free fatty acids, and glycerin in the small intestine and absorbed by the intestinal mucosa⁴

When absorbed from the digestive tract, Caprylic/Capric Triglyceride is hydrolyzed, and the fatty acids are catabolized to C₂ fragments which may be further metabolized either to CO₂ or to form long-chain fatty acids.⁵ Caprylic/Capric Triglyceride can undergo hydrolysis by enzymatic or chemical means to produce free fatty acids, partial glycerides, and glycerin. The free fatty acids may, in turn, undergo enzymatic β -oxidation. β -Oxidation of caprylic acid forms β -ketocaprylic acid and can be further oxidized to yield acetic acid and C₆-acid.

Caprylic/Capric Triglyceride and Triglycerides (general)

Oral absorption and metabolism of foods containing long-chain triglycerides (LCT) mixtures (alkyl chain lengths greater than 12 (C > 12)) differ from those containing Caprylic/Capric Triglyceride.²⁸ C > 12 are degraded by salivary, intestinal and pancreatic lipases into two fatty acids and a monoacyl glycerol, whereas, Caprylic/Capric Triglyceride is degraded by the same enzymes into three fatty acids and the simple glycerol backbone. Caprylic/Capric Triglyceride is readily absorbed from the small intestine directly into the bloodstream and transported to the liver for hepatic metabolism, while C > 12 are incorporated into chylomicrons and enter the lymphatic system. Caprylic/Capric Triglyceride is readily broken down to carbon dioxide and two-carbon fragments, while C > 12 are re-esterified to triacylglycerols and either metabolized for energy or stored in adipose tissue.

Tripelargonin and Triethylhexanoin

The primary metabolite of Triethylhexanoin, along with glycerol and monoglycerides, is 2-ethylhexanoic acid.²⁵

Groups of 5 newborn Rhesus (*Macaca mulatta*) monkeys were administered 8.4 ml/kg bw Tripelargonin, Triethylhexanoin, or water (control) via nasogastric (NG) tube.²⁹ Plasma C8:0 and C9:0 fatty acids and whole blood D-(-)-3-hydroxybutyrate (3HB) levels were measured 0, 1, and 3 h after dosing. Free fatty acid concentrations and ketone 3HB increased with time. C8 and C9 levels did not differ at 1 or 3 h, but at 1 h, blood 3HB concentrations were higher with Triethylhexanoin compared to animals dosed with Tripelargonin.

Groups of 8 New Zealand male rabbits were given a Tripelargonin/LCT (7/3 wt/wt) emulsion via a total parenteral nutrition (TPN) infusion regimen 7 h/day for 11 days.³⁰ The 3HB concentrations were significantly decreased, and plasma concentrations of propionic, acetic, butyric, and valeric acids were significantly increased. Following overnight fasting on days 9 and 12, fatty glycerol concentrations were statistically significantly increased compared to controls that were fed a standard diet, and on day 12, fasted rabbits were found to have increased triglyceride and non-esterified fatty acid levels.

TOXICOLOGICAL STUDIES

Acute Toxicity Studies

In acute oral toxicity studies in which Trihydroxystearin was tested using albino rats, the LD₅₀ was not achieved at a dose of 5 g/kg and no deaths were reported.¹

Acute oral LD₅₀ values range from 5 g/kg in mice (Tribehenin) to > 20 g/kg in rats (Tristearin).⁴ In other acute oral toxicity studies, Triethylhexanoin [Trioctanoin] was not toxic following oral administration to male mice at a dose of 50 ml/kg, and Triisostearin did not induce toxicity in rats at a dose of 2 g/kg.

Acute oral LD₅₀ values for Caprylic/Capric Triglyceride were > 25 ml/kg in mice and >5 g/kg in rats.⁵ Male rats and guinea pigs in groups of ten each were exposed for 6 h in a 40 L chamber containing an aerosol of Caprylic/Capric Triglyceride at a nominal concentration of 28.1 μ l/l of air. The fraction of the aerosol with particles small enough to be inhaled into the lung, i.e., with a diameter of 5 μ m or less, represented 1.97 μ l/l of the test substance. No adverse effects were observed.

The acute dermal and oral toxicity studies summarized below are described in [Table 8](#).

The dermal LD₅₀ in rats was >2 g/kg (the highest dose tested) for both Triheptanoin³¹ and Tristearin.³² The oral LD₅₀ was >2 g/kg for Triisostearin in mice and rats,³³ >2 g/kg Triolein in mice,³⁴ >5 g/kg Triheptanoin in mice, and >48 g/kg Triethylhexanoin³⁵ in rats. The oral LD₅₀ of an MLCT oil was >5 g/kg in rats.²⁸ A single dose of 8.4 ml/kg bw Tripelargonin and Triethylhexanoin, administered via NG tube, did not affect activity level or induce narcolepsy in newborn Rhesus (*Macaca mulatta*) monkeys.²⁹

Short-Term Toxicity Studies

The short-term oral administration of Trilaurin, Tristearin, or Triolein to weanling rats did not result in gross or microscopic lesions.⁴ However, in another short-term study, significant differences in hematological and clinical chemistry parameters as well as organ weights were noted after administration of Tricaprylin to male and female Wistar rats.

No signs of toxicity were observed in rabbits following 4 wks of applications of a tanning butter formulation containing 22% Caprylic/Capric Triglyceride at a dose of 2 g/kg, five times/wk for 4 wks, to intact and abraded skin.⁵ Two groups of 10 rats were dosed by gavage with 7.6 or 21.3 ml/kg undiluted Caprylic/Capric Triglyceride daily for 30 day.⁵ With the exception of a few gross observations made in the high-dose group in the first week of the study, no adverse effects were observed.

The short-term oral and intravenous (i.v.) toxicity studies summarized below are described in [Table 9](#).

In 28-day gavage studies in Han-Wistar rats, dosing with 3.12 g/kg 33% Caprylic/Capric Triglyceride did not produce any signs of toxicity,³⁶ but undiluted test material produced some gastrointestinal effects, decreased thymic weight, caused inflammation in the lungs, and resulted in changes in some clinical pathology parameters.³⁷ These changes were reversible. In Göttingen minipigs, clinical signs of toxicity were observed with 0.5 and 2 ml/kg/day Caprylic/Capric Triglyceride administered by gavage; no changes in organ weights or gross or microscopic lesions were observed.³⁸ In rats, a no-observed adverse effect level (NOAEL) of 10 mg/kg bw/day was reported in a 30 day study with Caprylic/Capric Triglyceride,³⁹ and a NOAEL of 3500 mg/kg/day was reported with MLCT.²⁸ In a human study, no adverse effects were observed in a placebo-controlled double-blind study in which healthy subjects ingested 42 g/day MLCT.²⁸

No adverse effects were observed in a study in which rabbits were given a Tripelargonin/LCT emulsion via a TPN infusion regimen for 7 h/day for 11 days.^{30,40}

Subchronic Toxicity Studies

Application of a perfumed skin softener formulation containing 4% Caprylic/Capric Triglyceride to the shaved skin of female rats at a dose of 2 ml/kg 5 days/wk for 13 wks did not produce any toxic effects.⁵ No toxic effects were noted in a 3-mos feeding study of 1 and 5% Caprylic/Capric Triglyceride in the diet of rats.

The subchronic toxicity studies summarized below are described in [Table 9](#).

Three-month feeding studies were performed with Caprylic/Capric Triglyceride in rats³⁹ and dogs.⁴¹ The NOAELs were 5% and 15%, respectively, and no toxicologically-relevant signs of toxicity were observed at the highest doses.

Chronic Toxicity Studies

No significant differences were found in growth rate or the incidence of lesions between groups of rats fed a mixture containing 0.0002% Trilaurin for 2 years and controls.⁴ In another chronic study, cardiac lipodosis and/or focal fibrosis was observed in rats fed a basal diet consisting of 30 cal % Trierucin for 24 weeks. Renal tubular dilatation, proteinaceous casts, or fibrosis were also reported. When the chronic oral toxicity of Tricaprylin was evaluated using groups of male rats, significant reductions in hematological/clinical chemistry parameters (10 ml/kg group) and significant increases in the liver (2 ml/kg) and adrenal gland weights (2 and 10 ml/kg) were noted after 26 weeks of dosing. Few lesions in the kidneys, myocardium, and aorta were noted when Tricaprylin was tested in another chronic oral toxicity study.

In studies in which rats were fed a diet containing 19.6% of a MCT composed of about 75% caprylic acid and 25% capric acid for 47 weeks or an MCT at 20% in the diet, for 1 yr, nutritional effects resulting from long-term consumption of this ingredient were observed, but no effects were interpreted as adverse or toxic.⁵

In a 9-mos feeding study, an oil containing 64% Triheptanoin was not toxic in rats [Table 9](#).⁴²

DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART) STUDIES

Tricaprylin (≤10 ml/kg) was not teratogenic in mice or rats when administered orally.⁴ In another study on reproductive effects, a uterine injection on 0.1 ml Tricaprylin was effective in producing fusion of the endometrial epithelium (symplesma formation) and decidualization of the stroma in pseudopregnant New Zealand white rabbits. The oral administration of 4750 mg/kg/day Triethylhexanoin [Trioctanoin] on days 6-13 of gestation to mice did not result in any significant differences in indices of potential developmental toxicity (i.e., litter size, birth weight, and neonatal growth and survival to postnatal day 3) between test and control groups. Test results for 291 fetuses from various strains of mice injected intraperitoneally with 0.5 mmol/kg bw Triethylhexanoin [Trioctanoin; was the vehicle control in a teratogenicity study] on days 8 and 12 of gestation indicated various kinds of eye abnormalities in 6.2% of the fetuses.

In a reproduction study, young adult male and female rats were fed a balanced diet containing 19.6% of a triglyceride of 75% caprylic and 25% capric acid for three weeks before mating.⁵ Litter size and birth weight of the test animals were

similar to those of rats on conventional or low fat diets, but mortality during lactation was somewhat higher, and there was less weight gain due to a smaller volume of milk secreted. After weaning, the F_1 generation was fed as the F_0 generation had been and showed a weight gain comparable to that of control rats.

Tricaprylin

In a study evaluating the developmental toxicity of trichloroacetonitrile in which Tricaprylin was used as a vehicle, a possibly biologically significant effect (increased resorptions, reduced fetal weight, and anomalies) was observed in the Tricaprylin control group when compared to the water control group.⁴³ Therefore, the developmental toxicity of trichloroacetonitrile was reexamined using Tricaprylin and corn oil as vehicles. Groups of 20 gravid Long-Evans rats were dosed by gavage on days 6-18 of gestation with 15 mg/kg/day trichloroacetonitrile in Tricaprylin and 15-75 mg/kg/day trichloroacetonitrile in corn oil; vehicle control groups were dosed with Tricaprylin, corn oil only, and water. The dosing volume was 10 ml/kg. All dams were killed on day 20 of gestation.

Statistically significant difference in some parameters was observed in the Tricaprylin control group compared to the water and/or corn oil control groups. There was a statistically significant increase in the percent implantation loss in the Tricaprylin (only) group as compared to both the water and corn oil controls, and the total implants/litter was statistically significantly less when compared to the corn oil, but not the water, control group. Also, there were statistically significant decreases in fetal body weights and crown-rump length in the Tricaprylin control group as compared to the water and corn oil control groups. There was no statistically significant difference in the incidence of fetal anomalies among the three control groups. In the dams, the maternal average kidney weight was statistically significantly increased in the Tricaprylin controls when compared to the water and corn oil controls; no effect on liver or spleen weight was reported.

The study authors postulated that the differences observed between the Tricaprylin group and the other two control groups may be attributable to potential changes in nutritional status. Dams of the Tricaprylin group gained significantly less weight than those of the corn oil group during days 15-18 of gestation. However, food and water consumption were not monitored. The study authors also stated that the differences in reproductive parameters could be due to normal variation for Long-Evans rats.

Additionally, the developmental toxicity of trichloroacetonitrile appeared to be vehicle-dependent; developmental effects caused by trichloroacetonitrile were seen at higher doses when administered in corn oil compared to those seen when Tricaprylin was used as the vehicle. The study authors suggested that trichloroacetonitrile and Tricaprylin “appear to interact in some way to potentiate effects of the cardiovascular system.” The adverse effects of trichloroacetonitrile in Tricaprylin were seen at doses as low as 1 mg/kg/d and included a number of different kinds of heart defects.

GENOTOXICITY STUDIES

In Vitro

*Ames test results indicated that Trihydroxystearin was not mutagenic to the following Salmonella typhimurium strains, with or without metabolic activation, when tested at concentrations ranging from 3 to 1000 µg/plate: TA1535, TA1537, TA1538, TA98, and TA100.*¹

*In the Ames test, Tricaprylin was mutagenic in one of four S. typhimurium strains tested.*⁴ *Negative test results were reported for Trilaurin in the following assays: dominant lethal test, host-mediated mitotic gene conversion assay, chromosomal aberrations assay, micronucleus test, sister chromatid exchange (SCE) assay, spot test for gene mutations, and cytogenetic assay for clastogenic activity. In the Ames test, Trilaurin, Triethylhexanoin [Trioctanoin], Triolein, Tristearin, and Triisostearin were not mutagenic in S. typhimurium strains. However, Triethylhexanoin [Trioctanoin] was mutagenic in the spot test for gene mutations. In other tests, no clastogenic activity was noted when Triethylhexanoin [Trioctanoin] was tested in a cytogenetics assay and results were negative in a sister chromatid exchanges mutagenicity assay.*

The genotoxicity studies summarized below are described in [Table 10](#).

Tristearin (5000 µg/plate)³² and Tricaprylin (concentration not stated)³⁵ were not mutagenic in the Ames test, Triethylhexanoin was not genotoxic in an Ames test (50-5000 µg/plate) or a mammalian chromosomal aberration assay (7.5-4000 µg/ml),²⁵ and Triisononoin was not genotoxic in an Ames test (50-5000 µg/plate), chromosomal aberration assay (10-320 µg/ml), or a mammalian cell gene mutation assay (5-80 µg/ml).⁴⁴

A lipid emulsion that comprises a mixture of soybean oil, Caprylic/Capric Triglyceride, olive oil, and fish oil (test concentrations not provided) was not genotoxic in an Ames test, a chromosomal aberration assay, or a hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assay.²⁷ In vivo, the emulsion was not genotoxic in a bone marrow cytogenic study in rats.

CARCINOGENICITY STUDIES

*Following intraperitoneal injection of 0.25 ml Tricaprylin into 30 female mice in a tumorigenicity study, lung tumors were observed in 37% of the animals.*⁴ *In the untreated-control group of 30 mice, the lung tumor incidence was 23%. The results of an oral carcinogenicity study by the National Toxicology Program (NTP) indicated that Tricaprylin caused a statistically significant dose-related increase in the incidence of pancreatic acinar cell hyperplasia and adenoma in rats. Tricaprylin did*

not induce acinar cell carcinomas. Additionally, the incidence of squamous cell papilloma in the squamous portion of the stomach of rats in the highest dose group (10 ml/kg Tricaprylin) was significantly greater when compared to controls.

ANTI-CARCINOGENICITY STUDIES

Trilaurin (dose not specified) completely inhibited the formation of neoplasms initiated by 7,12-dimethylbenz[a]anthracene (DMBA) and promoted by croton oil.⁴ Additionally, extensive damage to tumor cells (lymphoma implants in the liver) was noted in rats after oral dosing with Tricaprylin.

DERMAL IRRITATION AND SENSITIZATION STUDIES

Trihydroxystearin was not irritating to the skin of albino rabbits in 24-hour occlusive patch tests.¹ In 48-hour occlusive patch tests, Trihydroxystearin did not induce skin irritation in any of the 103 subjects tested.

Undiluted Triisostearin and a 20% solution of Tribehenin (0.5 ml) in liquid paraffin were, at most, mildly irritating when applied to the skin of rabbits.⁴ Undiluted Triethylhexanoin [Trioctanoin] and an eyeliner containing 36.3% Trilaurin did not induce cutaneous irritation in rabbits. Neither Tribehenin (test concentration not provided) nor Triethylhexanoin [Trioctanoin; 1% intradermal induction, 100% occlusive topical induction; 25% occlusive challenge] induced sensitization in the Magnusson-Kligman guinea pig maximization test. Triisostearin (0.02 ml/cm²) did not induce significant cutaneous reactions in a study evaluating the phototoxicity and photoallergenicity potential of this ingredient in guinea pigs.

An eyeliner containing 36.3% Trilaurin did not induce skin irritation reactions in 91 test subjects.⁴ Triethylhexanoin [Trioctanoin; details not provided] did not induce skin irritation in 25 subjects. A lip enhancer cream containing 0.38% Tribehenin was not comedogenic and did not induce clinically significant skin irritation in any of the 18 subjects evaluated in a 28-day test. Repeated insult patch test (RIPT) results (occlusive patches) for the following products were negative: eye enhancer cream containing 0.32% Tribehenin (198 subjects), hand cream containing 0.38% Tribehenin (at least 200 subjects), lip cream containing 0.38% Tribehenin (at least 200 subjects), and an eye defining pencil containing 1.68% Tristearin. None of these products induced clinically significant irritant or allergic contact dermatitis. In a skin sensitization test involving 91 subjects, there was no evidence of delayed contact hypersensitivity after repeated applications (occlusive patches) of an eyebrow pencil containing 40% Trilaurin. Also, Triethylhexanoin [Trioctanoin; details not provided] did not induce sensitization in a contact allergy test.

Application of a perfumed skin softener formulation containing 4% Caprylic/Capric Triglyceride to the shaved skin of female rats at a dose of 2 ml/kg 5 days/wk for 13 wks did not result in any localized skin effects. Caprylic/Capric Triglyceride was not a sensitizer in guinea pigs. Undiluted Caprylic/Capric Triglyceride was not irritating when tested using groups of 12 (21-day patch test), or 40 (test methods not described), and it was not an irritant or sensitizer in 128, subjects (Draize repeated insult patch test).

The dermal irritation and sensitization studies summarized below are described in [Table 11](#).

Dermal effects were observed in 4-h semi-occlusive patch tests in rabbits with undiluted Triheptanoin; very slight to slight erythema was reported in 1-2 of 3 animals in one study, but in the other study, very slight to well-defined erythema was observed in all 6 animals 30-60 min after patch removal, moderate to severe erythema and severe edema, discoloration, and dryness with sanguineous lacerations and scaling was observed in 1 animal 24-72 h after dosing, and scaling was observed in all animals at day 6.³¹ Triisostearin (test concentration not provided) produced well-defined erythema in all 3 rabbits at 1 and 24 h; all erythema was resolved by 72 h.³³ No irritation was observed in 4-h patch tests with undiluted Tristearin,³² Caprylic/Capric Triglyceride,³⁹ or C8-C12 Acid Triglycerides.³⁹ Triheptanoin (100%)³¹ and Tristearin (50%)³² were not sensitizers in guinea pigs. Triisnonanoin was predicted to be non-irritating in an EpiSkin™ in vitro test.⁴⁴ However, in a mouse local lymph node assay (LLNA), it was predicted that Triisnonanoin may cause sensitization; results were negative with 25% and 50% Triisnonanoin, but positive when tested at 100%.⁴⁴

A facial oil containing 95.51% Caprylic/Capric Triglyceride was not an irritant in a 24-h single insult occlusive patch test in 17 human subjects,⁴⁵ and it was not a sensitizer in a human modified maximization patch test with 26 subjects.⁴⁶ In human repeated insult patch tests, a moisturizer containing 6% Tribehenin was not a sensitizer (102 subjects),⁴⁷ and a mixture containing 20% Tribehenin had no clinically significant potential for dermal irritation or sensitization (52 subjects).⁴⁸ Triolein was not a sensitizer in a chamber test; details were not provided.³⁵

PHOTOSENSITIZATION

Caprylic/Capric Triglyceride

The photosensitization potential of a facial cream oil containing 95.51% Caprylic/Capric Triglyceride was evaluated in a RIPT photocontact allergenicity assay completed in 27 subjects.⁴⁹ For induction, an occlusive patch consisting of 40 mg of the test material spread uniformly onto a 2 x 2 cm (10 mg/cm²) cotton cloth was applied to the lower back of each subject for 24 h; immediately following patch removal, the test site was exposed to two minimal erythema doses (MEDs) from a xenon arc solar simulator. This procedure was repeated 2x/wk for 3 wks, for a total of 6 induction applications. The light source was a 150 W compact xenon arc solar simulator (Solar Light Company) equipped with a UV-reflecting dichroic mirror and a 1 mm thick Schott WG320 filter; a 1 mm thick UG11 filter was also used. The solar spectrum (SSR waveband) was used to

determine the individual MED. The size of the irradiated field at skin level was approximately a 1cm diameter circle. Total irradiance at skin level was 90.0 mW/cm². The UVA intensity was 52.5 mW/cm².

Following a 10-day non-treatment period, a challenge patch was applied for 24 h to a previously untreated site on the opposite side of the back, followed by exposure to ½ MED of solar simulated radiation plus 4 J/cm² of UVA. (For the challenge, a 1 mm thick Schott WG-345 filter was added to eliminate the UVB component (290-320 nm) and to produce a continuous broadband UVA extending from 320 to 410nm.) An unirradiated site treated with the test product served as a "dark" control. The sites were examined at 48 and 72 hours after irradiation for evidence of photocontact sensitization. The facial oil containing 95.51% Caprylic/Capric Triglyceride did not possess a detectable photocontact-sensitizing potential in human skin.

OCULAR IRRITATION STUDIES

Trihydroxystearin was classified as a mild, transient ocular irritant in albino rabbits.¹

An eye enhancer cream containing 0.32% Tribehenin and a hand cream containing 0.38% Tribehenin were classified as non-irritants in an in vitro chorioallantoic membrane vascular assay for determining the ocular irritation potential of chemicals.⁴ An eyeliner containing 36.3% Trilaurin and a 20% solution of Tribehenin in liquid paraffin were, at most, mildly irritating to the eyes of rabbits. Triethylhexanoin [Trioctanoin] and Triisostearin did not induce ocular irritation in rabbits.

An eye enhancer cream containing 0.32% Tribehenin induced reactions ranging from mild to moderate ocular irritation in a group of 20 subjects, which resolved to either mild irritation or no irritation reactions at 2 hours post exposure.⁴ In a clinical in-use safety test of two eye enhancer creams containing 0.32% Tribehenin, neither ocular irritation nor clinically relevant alterations in visual acuity were observed after 4 consecutive weeks of daily product use. Similar results were reported after testing of another eye enhancer cream containing 0.32% Tribehenin and an eye defining pencil containing 1.68% Tristearin in separate studies according to the same procedure. All of the subjects tested in these studies were contact lens wearers.

Caprylic/Capric Triglyceride was non-irritating, to at most very mildly irritating, to rabbit eyes.⁵

The ocular irritation studies summarized below are described in [Table 12](#).

Undiluted Triheptanoin,³¹ Tristearin,³² Caprylic/Capric Triglyceride,³⁹ and C8-12 Acid Triglyceride,³⁹ as well as Triisostearin at an unspecified concentration,³³ were not irritating in rabbit eyes. Triisononoin was predicted to be non-irritating in an in vitro eye irritation test using the SkinEthic™ reconstructed model.⁴⁴

SUMMARY

In 2000, the Panel assessed the safety of Trihydroxystearin and concluded that, based on the available animal and clinical data, which included summary data from the CIR safety assessments of Hydroxystearic Acid and Glyceryl Stearate and Glyceryl Stearate SE, Trihydroxystearin is safe as used in cosmetics. The Panel published two additional reports on related ingredients; the Panel concluded that Caprylic/Capric Triglyceride (1980) and Trilaurin and 22 additional glyceryl triesters (2001) are safe as used in cosmetics. An additional 29 triglycerides that are cosmetic ingredients and have not been reviewed by the Panel have also been identified. This safety assessment is a compilation of these 51 triglycerides, most of which (but not all) function as skin conditioning agents and/or viscosity increasing agents in cosmetics.

Some of these triglycerides are produced synthetically via classical Fischer type esterification methods, although the reaction may be promoted by acid or base catalysis, or by the use of an acid chloride. Additionally, some of these ingredients may be natural sourced and produced by transesterification.

Thirty-one of the 51 ingredients included in this safety assessment are in use, and Caprylic/Capric Triglyceride has the highest frequency of use (6000 formulations). According to the results of a concentration of use survey conducted by the Council, Triethylhexanoin has the highest maximum use concentration, with concentrations of 100% reported for face and neck formulations and 63% in lipstick formulations.

Approximately half of the ingredients included in this safety assessment have been reviewed previously by the Panel. The frequency and maximum concentrations of use for the majority of these ingredients have generally increased since these ingredients were originally reviewed.

Many of the triglycerides are approved by the FDA for use as direct or indirect food additives.

Oral absorption and metabolism of foods containing LCT mixtures differ from those containing Caprylic/Capric Triglyceride. C > 12 are degraded by salivary, intestinal and pancreatic lipases into two fatty acids and a monoacyl glycerol, whereas, Caprylic/Capric Triglyceride is degraded by the same enzymes into three fatty acids and the simple glycerol backbone.

In newborn Rhesus monkeys administered a single dose of Tripelargonin or Triethylhexanoin via NG tube, free fatty acid concentrations and ketone 3HB increased with time. In New Zealand male rabbits given a Tripelargonin/LCT emulsion via a TPN infusion regimen 7 h/day for 11 days, 3HB concentrations were significantly decreased and plasma concentrations of short-chain fatty acids were significantly increased.

In acute toxicity testing, the dermal LD₅₀ in rats was > 2 g/kg (the highest dose tested) for both Triheptanoin and Tristearin. The oral LD₅₀ was > 2 g/kg for Triisostearin in mice and rats, > 2 g/kg Triolein in mice, > 5 g/kg Triheptanoin in mice, and > 48 g/kg Triethylhexanoin in rats. The oral LD₅₀ of a MLCT oil was > 5 g/kg in rats. A single dose of 8.4 ml/kg bw Tripelargonin and Triethylhexanoin, administered via NG tube, did not affect activity level or induce narcolepsy in newborn Rhesus monkeys.

In 28-day gavage studies in Han-Wistar rats, dosing with 33% Caprylic/Capric Triglyceride did not produce any signs of toxicity, but undiluted test material produced some gastrointestinal effects, decreased thymic weight, caused inflammation in the lungs, and resulted in changes in some clinical pathology parameters. These changes were reversible. In Göttingen minipigs, clinical signs of toxicity were observed with 0.5 and 2 ml/kg/day Caprylic/Capric Triglyceride administered by gavage; no changes in organ weights or gross or microscopic lesions were observed. No adverse effects were observed in a study in which rabbits were given a Tripelargonin/LCT emulsion via a TPN infusion regimen for 7 h/day for 11 days

Short-term and subchronic feeding studies were conducted with Caprylic/Capric Triglyceride. In rats, a NOAEL of 10 mg/kg bw/day was reported in a 30 day study with Caprylic/Capric Triglyceride, and a NOAEL of 3500 mg/kg/day was reported with mixture of triglycerides with alkyl chain lengths C8-C24. In a human study, no adverse effects were observed in a placebo-controlled double-blind study in which healthy subjects ingested 42 g/day of the C8-C24 mixture. Three-month feeding studies were performed with Caprylic/Capric Triglyceride in rats and dogs, and the NOAELs were 5% and 15%, respectively; no toxicologically-relevant signs of toxicity were observed at the highest doses.

In a chronic (9-mos) feeding study, an oil containing 64% Triheptanoin was not toxic in rats.

Tricaprylin was used as a vehicle in an oral (gavage) DART study of trichloroacetonitrile, and its effect on the test results was compared to other vehicles. Additionally, the potential developmental toxicity of Tricaprylin was evaluated in comparison to the two other vehicles (water and corn oil). There was a statistically significant increase in the percent implantation loss in the Tricaprylin group as compared to both the water and corn oil controls, and the total implants/litter was statistically significantly less when compared to the corn oil, but not the water, control group. Also, there were statistically significant decreases in fetal body weights and crown-rump length in the Tricaprylin control group as compared to the water and corn oil control groups. The study authors postulated that the differences observed between the Tricaprylin group and the other two control groups may be attributable to potential changes in nutritional status.

Additionally, the developmental toxicity of trichloroacetonitrile appeared to be vehicle-dependent; developmental effects caused by trichloroacetonitrile were seen at higher doses when administered in corn oil compared to those seen when Tricaprylin was used as the vehicle. The study authors suggested that trichloroacetonitrile and Tricaprylin “appear to interact in some way to potentiate effects of the cardiovascular system.”

The genotoxicity of several triglycerides was evaluated, and all the results were negative. Tristearin (5000 µg/plate) and Tricaprylin (concentration not stated) were not mutagenic in the Ames test, Triethylhexanoin was not genotoxic in an Ames test (50-5000 µg/plate) or a mammalian chromosomal aberration assay (7.5-4000 µg/ml), and Triisononanoin was not genotoxic in an Ames test (50-5000 µg/plate), chromosomal aberration assay (10-320 µg/ml), or a mammalian cell gene mutation assay (5-80 µg/ml).

A lipid emulsion that comprises a mixture of soybean oil, Caprylic/Capric Triglyceride, olive oil, and fish oil (test concentrations not provided) was not genotoxic in an Ames test, a chromosomal aberration assay, or a hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assay. In vivo, the emulsion was not genotoxic in a bone marrow cytogenic study in rats.

Mixed results were obtained in dermal irritation and sensitization studies. Dermal effects were observed in 4-h semi-occlusive patch tests in rabbits with undiluted Triheptanoin; very slight to slight erythema was reported in 1-2 of 3 animals in one study, but in the other, very slight to well-defined erythema was observed in all 6 animals 30-60 min after patch removal, moderate to severe erythema and severe edema, discoloration, and dryness with sanguineous lacerations and scaling was observed in 1 animal 24-72 h after dosing, and scaling was observed in all animals at day 6. Triisostearin (test concentration not provided) produced well-defined erythema in all 3 rabbits at 1 and 24 h; all erythema was resolved by 72 h. No irritation was observed in 4-h patch tests with undiluted Tristearin, Caprylic/Capric Triglyceride, or C8-C12 Acid Triglycerides. Triheptanoin (100%) and Tristearin (50%) were not sensitizers in guinea pigs. Triisononanoin was predicted to be non-irritating in an EpiSkin™ in vitro test. However, in a mouse LLNA, it was predicted that Triisononanoin may cause sensitization; results were negative with 25% and 50% Triisononanoin but positive when tested at 100%.

In human testing, a facial oil containing 95.51% Caprylic/Capric Triglyceride was not an irritant in a 24-h single insult occlusive patch test in 17 subjects, was not a sensitizer in a human modified maximization patch test with 26 subjects, and was not a photosensitizer. In HRIPTs, a moisturizer containing 6% Tribehenin was not a sensitizer (102 subjects), and a mixture containing 20% Tribehenin had no clinically significant potential for dermal irritation or sensitization (52 subjects). Triolein was not a sensitizer in a chamber test; details were not provided.

Several triglycerides were evaluated and found not to be ocular irritants. Undiluted Triheptanoin, Tristearin, Caprylic/Capric Triglyceride, and C8-12 Acid Triglyceride, as well as Triisostearin at an unspecified concentration, were not irritating in

rabbit eyes. Triisononoin was predicted to be non-irritating in an in vitro eye irritation test using the SkinEthic™ reconstructed model.

No new carcinogenicity data were discovered in an extensive search of the published literature.

DISCUSSION

In accordance with its procedures, the CIR evaluates the conclusions of previously-issued reports every 15 years. The Panel has issued three final reports on the safety of 25 triglycerides (i.e., fatty acid triesters of glycerin) in the past 15+ years. The Panel previously concluded that Trihydroxystearin (2000), Caprylic/Capric Triglyceride (1980; reaffirmed in 2003), and a family of ingredients that included Trilaurin and 22 additional glyceryl triesters (2001) are safe as used in cosmetics. Additionally, the Panel determined that it was appropriate to include 26 triglycerides that have not yet been reviewed. The collection of these ingredients in one report enables the assembly of reinforcing and complementary test data. Safety profiles of these ingredients are consistent with roles of most constituents as dietary components and safe conclusions in previous reports.

Upon initial review of the safety of the triglycerides as used in cosmetics at its April 10-11, 2017 meeting, the Panel determined additional data were needed to assess the safety of these ingredients and issued an Insufficient Data Announcement (IDA). Many, but not all, of the data requests were satisfied.

The main focus of the IDA was for irritation and sensitization data at concentration of use on four ingredients (i.e., Tribehenin, Caprylic/Capric Triglyceride, Triethylhexanoin, and C10-40 Isoalkyl Acid Triglyceride). Data were received for two of the four ingredients (i.e., Tribehenin and Caprylic/Capric Triglyceride), and the Panel acknowledged the negative results obtained in a guinea pig maximization study (1% intradermal induction, 100% occlusive topical induction; 25% occlusive challenge) that was reported in the previous (2001) report. Although data were not received on all four ingredients included in the IDA, the Panel stated that the weight of the evidence supported the safety of all the ingredients included in this report, and therefore their data needs were satisfied.

Approximately half of the ingredients in this safety assessment have been reviewed previously by the Panel. The frequency and maximum concentrations of use for the majority of these ingredients has increased when compared to the original review. The most remarkable increase is in the frequency of use of Caprylic/Capric Triglyceride; in 2003, this ingredient was reported to be used in 763 formulations and in 2017, it is reported to be used in 6000 formulations. Also, in 2003, the maximum leave-on concentration of use for Caprylic/Capric Triglyceride was 84%, it is now reported to 95.6% in face and neck products.

One reported possible function of Docosahexenoic/Docosapentenoic/Oleic/Palmitic Triglyceride is skin bleaching agent. In the United States, skin bleaching agent is not considered a cosmetic function, and therefore use in that manner is not being assessed in this report.

During its original review of Trilaurin and other glyceryl triesters, the Panel noted that, as part of an effort to evaluate vehicles used in carcinogenicity studies, the NTP conducted a 2-year carcinogenicity study in rats given Tricaprylin by gavage. This treatment was associated with a statistically significant dose-related increase in pancreatic acinar cell hyperplasia and adenoma, but there were no acinar carcinomas, the incidence of mononuclear leukemia was less, and nephropathy findings were reduced, compared to corn oil controls. In a tumor inhibition study, Trilaurin was found to inhibit the formation of neoplasms initiated by DMBA and promoted by croton oil. However, the Panel stated that no restrictions were warranted for any of these ingredients.

High purity is needed for the triglycerides. In 2007, the Panel published a final report on a diglycerides, and concluded that the ingredients in the diglyceride family are safe in the present practices of use and concentration provided the content of 1,2-diester is not high enough to induce epidermal hyperplasia. The Panel discussed that there was an increased level of concern because of data regarding the induction of protein kinase C (PKC) and the tumor promotion potential of 1,2-diacylglycerols. The Panel noted that, nominally, glyceryl-1,3-diester contain 1,2-diester, raising the concern that 1,2-diester could potentially induce hyperplasia. The Panel did note that these compounds are more likely to cause these effects when the fatty acid chain length is ≤ 14 carbons, when one fatty acid is saturated and one is not, and when given at high doses, repeatedly.

Based on existing information from a previous CIR safety assessment, minimal percutaneous absorption of Triolein has been demonstrated in vivo using guinea pigs (but not hairless mice), and in vitro using full-thickness skin from hairless mice. However, the Panel recognized that, reportedly, Triolein and Tricaprylin can enhance the skin penetration of other chemicals, and the Panel cautioned that care should be taken in formulating cosmetic products that may contain these ingredients in combination with any ingredients whose safety was based on their lack of dermal absorption data, or when dermal absorption was a concern.

The Panel acknowledged that some of the triglycerides may be formed from plant-derived or animal-derived constituents. The Panel thus expressed concern regarding pesticide residues and heavy metals that may be present in botanical ingredients. They stressed that the cosmetics industry should continue to use the necessary procedures to sufficiently limit amounts of such impurities in an ingredient before blending them into cosmetic formulations. Additionally, the Panel considered the risks inherent in using animal-derived ingredients, namely the transmission of infectious agents. Although tallow may be used in

the manufacture of Cod Liver/Mink/Tallow Triglyceride and is clearly animal-derived, the Panel notes that tallow is highly processed, and tallow derivatives even more so. The Panel agrees with determinations by the U.S. FDA that tallow derivatives are not risk materials for transmission of infectious agents.

Finally, the Panel discussed the issue of incidental inhalation exposure, as some of the triglycerides are used in cosmetic sprays and could possibly be inhaled. For example, Triethylhexanoin and Triisostearin are reported to be used at maximum concentrations of 36% and 30%, respectively, in perfumes, and 14.7% and 10.4%, respectively, in face powders. The Panel noted that in aerosol products, 95% – 99% of droplets/particles would not be respirable to any appreciable amount. Furthermore, droplets/particles deposited in the nasopharyngeal or bronchial regions of the respiratory tract present no toxicological concerns based on the chemical and biological properties of these ingredients. Coupled with the small actual exposure in the breathing zone and the concentrations at which the ingredients are used, the available information indicates that incidental inhalation would not be a significant route of exposure that might lead to local respiratory or systemic effects. A detailed discussion and summary of the Panel's approach to evaluating incidental inhalation exposures to ingredients in cosmetic products is available at <http://www.cir-safety.org/cir-findings>

CONCLUSION

The CIR Expert Panel concluded that the following 51 triglycerides are safe in cosmetics in the present practices of use and concentration described in this safety assessment:

Acetic/Linoleic/Palmitic Triglyceride*	Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride*
C12-18 Acid Triglyceride	Palmitic/Stearic Triglyceride
C18-36 Acid Triglyceride	Ricinoleic/Caproic/Caprylic/Capric Triglyceride*
C8-12 Acid Triglyceride*	Triarachidin*
Capric/Lauric/Myristic/Oleic Triglyceride*	Tribehenin
Caprylic/Capric Triglyceride	Tricaprin
Caprylic/Capric/Lauric Triglyceride	Tricaprylin
Caprylic/Capric/Linoleic Triglyceride	Tierucin*
Caprylic/Capric/Myristic/Stearic Triglyceride	Triethylhexanoin
Caprylic/Capric/Palmitic/Stearic Triglyceride*	Triheptanoin
Caprylic/Capric/Stearic Triglyceride	Triheptylundecanoin*
C10-40 Isoalkyl Acid Triglyceride	Trihydroxystearin
Cod Liver/Mink/Tallow Triglyceride*	Triisononanoin
C10-18 Triglycerides	Triisopalmitin*
Docosahexenoic/Docosapentenoic/Oleic/Palmitic Triglyceride*	Triisostearin
Glyceryl Stearate Diacetate*	Trilaurin
Glyceryl Triacetyl Hydroxystearate	Trilinolein
Glyceryl Triacetyl Ricinoleate	Trilinolenin
Glyceryl Tri-Hydrogenated Rosinate	Trimyristin
Glyceryl Tripalmitate/Palm	Triolein
Kernelate/Olivate/Macadamate/Rapeseedate*	Tripalmitin
Hydrogenated C12-18 Triglycerides	Tripalmitolein*
Isomerized Safflower Glycerides*	Tripelargonin*
Jobba Oil/Caprylic/Capric Triglyceride Esters*	Triricinolein*
Lauric/Palmitic/Oleic Triglyceride*	Tristearin
Oleic/Linoleic Triglyceride*	Triundecanoin

*Not reported to be in current use. Were ingredients in this group not in current use to be used in the future, the expectation is that they would be used in product categories and at concentrations comparable to others in this group.

TABLES

Table 1. Triglycerides included in this report

Acetic/Linoleic/Palmitic Triglyceride	Glyceryl Triacetyl Ricinoleate	Triheptanoin
C8-12 Acid Triglyceride	Glyceryl Tri-Hydrogenated Rosinate	Triheptylundecanoin
C12-18 Acid Triglyceride	Glyceryl Tripalmitate/Palm Kernelate/ Olivate/Macadamate/Rapeseedate	Trihydroxystearin
C18-36 Acid Triglyceride	Hydrogenated C12-18 Triglycerides	Triisononanoin
Capric/Lauric/Myristic/Oleic Triglyceride	Isomerized Safflower Glycerides	Triisopalmitin
Caprylic/Capric Triglyceride	Jojoba Oil/Caprylic/Capric Triglyceride Esters	Triisostearin
Caprylic/Capric/Lauric Triglyceride	Lauric/Palmitic/Oleic Triglyceride	Trilaurin
Caprylic/Capric/Linoleic Triglyceride	Oleic/Linoleic Triglyceride	Trilinolein
Caprylic/Capric/Myristic/Stearic Triglyceride	Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride	Trilinolenin
Caprylic/Capric/Palmitic/Stearic Triglyceride	Palmitic/Stearic Triglyceride	Trimyristin
Caprylic/Capric/Stearic Triglyceride	Ricinoleic/Caproic/Caprylic/Capric Triglyceride	Triolein
C10-40 Isoalkyl Acid Triglyceride	Triarachidin	Tripalmitin
Cod Liver/Mink/Tallow Triglyceride	Tribehenin	Tripalmitolein
C10-18 Triglycerides	Tricaprin	Tripelargonin
Docosahexenoic/Docosapentenoic/ Oleic/Palmitic Triglyceride	Tricaprylin	Tricicoleolin
Glyceryl Stearate Diacetate	Trierucin	Tristearin
Glyceryl Triacetyl Hydroxystearate	Triethylhexanoin (previously, Trioctanoin)	Triundecanoin

Note: ingredients that were previously reviewed are indicated in blue

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. ^{(7)(CIR Staff)}





Ingredient/CAS No.	Definition & Structure	Function(s)
	<i>Linear chain saturated triglycerides</i>	
Triheptanoin 620-67-7	Triheptanoin is the triester of glycerin and heptanoic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent – nonaqueous
Tricaprylin 538-23-8	Tricaprylin is the triester of glycerin and caprylic acid. It conforms to the formula: 	fragrance ingredient; skin conditioning agent – occlusive
Tripelargonin 126-53-4	Tripelargonin is the organic compound that conforms to the formula: 	skin conditioning agent – emollient
Tricaprin 621-71-6	Tricaprin is the triester of glycerin and capric acid. It conforms to the formula: 	fragrance ingredient; skin conditioning agent – occlusive

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])







Ingredient/CAS No.	Definition & Structure	Function(s)
Triundecanoin 13552-80-2	Triundecanoin is the triester of glycerin and undecanoic acid. It conforms to the formula: 	hair conditioning agent; skin conditioning agent – occlusive
Trilaurin 538-24-9	Trilaurin is the triester of glycerin and lauric acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Trimyristin 555-45-3	Trimyristin is the triester of glycerin and myristic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Tripalmitin 555-44-2	Tripalmitin is the triester of glycerin and palmitic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Tristearin 555-43-1	Tristearin is the triester of glycerin and stearic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Triarachidin 620-64-4	Triarachidin is the triester of glycerin and arachidic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])







Ingredient/CAS No.	Definition & Structure	Function(s)
Tribehenin 18641-57-1	Tribehenin is the triester of glycerin and behenic acid. It conforms to the formula: 	skin conditioning agent – occlusive
<i>Linear, mixed chain length saturated triglycerides</i>		
Glyceryl Stearate Diacetate 84931-78-2	Glyceryl Stearate Diacetate is the organic compound that conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent – nonaqueous
Caprylic/Capric Triglyceride 65381-09-1 73398-61-5	Caprylic/Capric Triglyceride is the mixed triester of glycerin and caprylic and capric acids.  [wherein RC(O)- is the residue of caprylic (C8) or capric (C10) acid.]	fragrance ingredient; skin conditioning agent – occlusive; solvent
Caprylic/Capric/Lauric Triglyceride 123465-33-8	Caprylic/Capric/Lauric Triglyceride is the mixed triester of glycerin with caprylic, capric and lauric acids.  [wherein RC(O)- is the residue of caprylic (C8), capric (C10), or lauric (C12) acid.]	skin conditioning agent – occlusive
C8-12 Acid Triglyceride	C8-12 Acid Triglyceride is the triester of glycerin and a mixture of saturated acids containing 8 to 12 carbons in the alkyl chain.  [wherein RC(O)- is the residue of a fatty acid 8, 10, or 12 carbons in length]	skin conditioning agent – occlusive; solvent; viscosity increasing agent - nonaqueous
Caprylic/Capric/Myristic/Stearic Triglyceride	Caprylic/Capric/Myristic/Stearic Triglyceride is the mixed triester of glycerin with caprylic, capric, myristic and stearic acids.  [wherein RC(O)- is the residue of caprylic, capric, myristic or stearic acid.]	skin conditioning agent – occlusive

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. ^{(7) [CIR Staff]}







Ingredient/CAS No.	Definition & Structure	Function(s)
Caprylic/Capric/Palmitic/ Stearic Triglyceride	Caprylic/Capric/Palmitic/Stearic Triglyceride is the mixed triester of glycerin with caprylic, capric, palmitic and stearic acids. 	skin conditioning agent – occlusive
[wherein RC(O)- is the residue of caprylic, capric, palmitic or stearic acid.]		
Caprylic/Capric/Stearic Triglyceride	Caprylic/Capric/Stearic Triglyceride is the mixed triester of glycerin with caprylic, capric and stearic acids. 	skin conditioning agent – occlusive
[wherein RC(O)- is the residue of caprylic, capric, or stearic acid.]		
C10-18 Triglycerides 85665-33-4	C10-18 Triglycerides is the triester of glycerin and a mixture of normal and branched chain C10-18 fatty acids. 	skin conditioning agent – occlusive; solvents
[wherein RC(O)- is the residue of a fatty acid 10, 12, 14, 16, or 18 carbons in length]		
C12-18 Acid Triglyceride	C12-18 Acid Triglyceride is the triester of glycerin and a synthetic mixture of saturated acids containing 12 to 18 carbons in the alkyl chain. 	skin conditioning agent – occlusive; solvent; viscosity increasing agent - nonaqueous
[wherein RC(O)- is the residue of a fatty acid 12, 14, 16, or 18 carbons in length]		
Palmitic/Stearic Triglyceride	Palmitic/Stearic Triglyceride is the triester of glycerin with a mixture of palmitic and stearic acids. 	viscosity increasing agent - nonaqueous
[wherein RC(O)- is the residue of palmitic or stearic acid]		
C18-36 Acid Triglyceride 91052-08-3	C18-36 Acid Triglyceride is the triester of glycerin and C18-36 Acid. It conforms to the formula 	skin conditioning agent – occlusive
[wherein RC(O)- is the residue of a fatty acid 18, 20, 22, 24, 26, 28, 30, 32, 34, or 36 carbons in length]		

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])






Ingredient/CAS No.	Definition & Structure	Function(s)
Branched chain triglycerides		
Triethylhexanoin (previously named Trioctanoin) 7360-38-5	Triethylhexanoin is the triester of glycerin and 2-ethylhexanoic acid. It conforms generally to the formula: 	fragrance ingredient; hair conditioning agent; skin conditioning agent – occlusive
Triisononanoin 206354-95-2 56554-53-1	Triisononanoin is the triester of glycerin and a branched chain nonanoic acid. It conforms generally to the formula:  one example of an “iso”	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Triisopalmitin 68957-79-9	Triisopalmitin is the triester of glycerin and a 16 carbon branched chain aliphatic acid. It conforms to the formula:  one example of an “iso”	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Triisostearin 26942-95-0	Triisostearin is the triester of glycerin and isostearic acid. [It conforms to the structure:]  one example of an “iso”	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Triheptylundecanoin 105214-66-2	Triheptylundecanoin is the triester of glycerin and heptylundecanoic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])







Ingredient/CAS No.	Definition & Structure	Function(s)
Branched, mixed length chain triglyceride		
C10-40 Isoalkyl Acid Triglyceride	C10-40 Isoalkyl Acid Triglyceride is the triester of glycerin and C10-40 Isoalkyl Acid.	hair conditioning agent; skin conditioning agent – emollient; viscosity increasing agent - nonaqueous
		
[wherein RC(O)- is the residue of a branched fatty acid 10 to 40 carbons in length]		
Unsaturated chain & hydroxy acid triglycerides		
Tripalmitolein 129784-33-4 20246-55-3	Tripalmitolein is the triester of glycerin and palmitoleic acid. It conforms to the formula:	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
		
Triolein 122-32-7 6915-08-8	Triolein is the triester of glycerin and oleic acid. It conforms to the formula:	skin protectant; skin conditioning agent – emollient, occlusive, misc; viscosity increasing agent - nonaqueous
		
Oleic/Linoleic Triglyceride	Oleic/Linoleic Triglyceride is the mixed triester of glycerin with oleic and linoleic acids.	skin conditioning agent – occlusive
		
[wherein RC(O)- is the residue of oleic or linoleic acid]		
Docosahexenoic/ Docosapentenoic/ Oleic/Palmitic Triglyceride	Docosahexenoic/Docosapentenoic/Oleic/Palmitic Triglyceride is the mixed triester of glycerin with docosahexenoic, docosapentenoic, oleic, and palmitic acids.	skin bleaching agent; skin protectant; skin conditioning agent – misc
		
[wherein RC(O)- is the residue of docosahexenoic, docosapentenoic, oleic, or palmitic acid.]		
Isomerized Safflower Glycerides 303101-61-3	Isomerized Safflower Glycerides is the product formed by the esterification of glycerin and isomerized safflower acid.	oral health care drug; skin conditioning agent - misc
		
[wherein RC(O)- is the residue of a fatty acid derived from safflower oil, which is approximately 68% linoleic, 25% oleic, and 2% palmitic] ⁵⁰		

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])






Ingredient/CAS No.	Definition & Structure	Function(s)
Trilinolein 537-40-6	Trilinolein is the triester of glycerin and linoleic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Trilinolenin 14465-68-0	Trilinolenin is the triester of glycerin and linolenic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Trierucin 2752-99-0	Trierucin is the triester of glycerin and erucic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Triricinolein 15505-14-3 2540-54-7	Triricinolein is the triester of glycerin and ricinoleic acid. It conforms to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
Trihydroxystearin 139-44-6	Trihydroxystearin is the triester of glycerin and hydroxystearic acid. It conforms generally to the formula: 	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous




Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. (7:[CIR Staff])

Ingredient/CAS No.	Definition & Structure	Function(s)
Acetylated hydroxyacid triglycerides		
Glyceryl Triacetyl Hydroxystearate 27233-00-7	Glyceryl Triacetyl Hydroxystearate is the triester of glycerin and acetyl hydroxystearic acid. It conforms to the formula:	skin conditioning agent - emollient
Glyceryl Triacetyl Ricinoleate 101-34-8	Glyceryl Triacetyl Ricinoleate is the triester of glycerin and acetyl ricinoleic acid. It conforms to the formula:	skin conditioning agent - emollient
Mixed chain – others (combinations of length, saturation, and branching variations)		
Acetic/Linoleic/Palmitic Triglyceride 221139-79-3	Acetic/Linoleic/Palmitic Triglyceride is the triester of glycerin with acetic, linoleic and palmitic acids.	skin conditioning agent – emollient; skin conditioning agent - humectant
[wherein RC(O)- is the residue of acetic, linoleic, or palmitic acid.]		
Capric/Lauric/Myristic/Oleic Triglyceride	Capric/Lauric/Myristic/Oleic Triglyceride is the mixed triester of glycerin with caprylic, capric, lauric, myristic and oleic acids.	skin protectant; skin conditioning agent – emollient; skin conditioning agent - misc
[wherein RC(O)- is the residue of caprylic, capric, lauric, myristic, or oleic acid.]		
Caprylic/Capric/Linoleic Triglyceride	Caprylic/Capric/Linoleic Triglyceride is the mixed triester of glycerin with caprylic, capric and linoleic acids.	skin conditioning agent - occlusive
[wherein RC(O)- is the residue of caprylic, capric, or linoleic acid.]		

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. ^{(7)[CIR Staff]}

Ingredient/CAS No.	Definition & Structure	Function(s)
Cod Liver/Mink/Tallow Triglyceride	Cod Liver/Mink/Tallow Triglyceride is a mixed triester of glycerin with the fatty acids derived from cod liver oil, mink oil, and tallow	skin conditioning agent – emollient; skin conditioning agent - occlusive
<p>[wherein RC(O)- is the residue of a fatty acid derived from cod liver oil (which is approximately 16.2% oleic acid, 11.9% docosahexaenoic acid, 10.4% palmitic acid, 9.4% gondoic acid (20:1 <i>n</i>-9), 9.3% eicosapentaenoic acid, 7.8% cetoleic acid (22:1 <i>n</i>-11), 6.5% palmitoleic acid, 4.4% <i>cis</i>-vaccenic acid, 3.6% myristic acid, 2.6% stearic acid, 2.4% morotic acid, 1.6% gadoleic acid (20:1 <i>n</i>-11), 1.5% linoleic acid,⁵¹ mink oil (which is approximately 35-41% oleic acid, 17-28% palmitic acid (16/0), 13-17% palmitic acid (16/1), and 11-15% linoleic acid),⁵² and tallow (which is approximately 37-43% oleic acid, 24-32% palmitic acid, 20-25% stearic acid, 3-6% myristic acid, and 2-3% linoleic acid)⁵³].</p>		
Glyceryl Tri-Hydrogenated Rosinate	Glyceryl Tri-Hydrogenated Rosinate is a triester of glycerin and the partially hydrogenated acids derived from Rosin	surfactant – emulsifying agent
[wherein RC(O)- is the residue of the partially hydrogenated acids derived from rosin.].		
Glyceryl Tripalmitate/ Palm Kernelate/Olivate/ Macadamiate/ Rapeseedate	Glyceryl Tripalmitate/Palm Kernelate/Olivate/Macadamiate/Rapeseedate is the triester of glycerin with a mixture of fatty acids derived from palm oil, palm kernel oil, olive oil, macadamia nut oil and rapeseed oil.	skin conditioning agent – emollient
<p>[wherein RC(O)- is the residue of a fatty acid derived from palm oil (which is approximately 44% palmitic acid, 39% oleic acid, and 10% linoleic acid), palm kernel oil (which is approximately 48% lauric acid, 16% myristic acid, and 15% oleic acid), olive oil (which is approximately 53-86% oleic acid and 7.5-20% palmitic acid.), macadamia oil (which is approximately 50-67% oleic acid, 12-25% palmitoleic acid, and 6-12% palmitic acid), and rapeseed oil (which is approximately 1-59% behenic acid, 12-57% oleic acid, 11-22% linoleic acid, and 8-12.5% linolenic acid)]⁵⁰</p>		
Hydrogenated C12-18 Triglycerides	Hydrogenated C12-18 Triglycerides is the end-product of controlled hydrogenation of C12-18 triglycerides.	skin conditioning agent – occlusive; viscosity increasing agent - nonaqueous
[wherein RC(O)- is the residue of hydrogenated of C12-18 acids]		
Jojoba Oil/Caprylic/Capric Triglyceride Esters	Jojoba Oil/Caprylic/Capric Triglyceride Esters is the product obtained by the transesterification of Simmondsia Chinensis (Jojoba) Seed Oil with Caprylic/Capric Triglyceride.	skin protectant; skin conditioning agent – emollient
<p>[wherein RC(O)- is the residue of caprylic acid, capric acid, and a fatty acid derived from jojoba, which is approximately 83% as combinations of arachidic and behenic acids⁵⁴]</p>		

Table 2. Definitions, idealized structures, and functions of the ingredients in this safety assessment. ^{(7) [CIR Staff]}

Ingredient/CAS No.	Definition & Structure	Function(s)
Lauric/Palmitic/Oleic Triglyceride	Lauric/Palmitic/Oleic Triglyceride is a mixed triester of glycerin with lauric, palmitic and oleic acids.  [wherein RC(O)- is the residue of lauric, palmitic, or oleic acid]	skin conditioning agent – occlusive
Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride	Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride is the mixed triester of glycerin with oleic, palmitic, lauric, myristic and linoleic acids.  [wherein RC(O)- is the residue of oleic, palmitic, lauric, myristic, or linoleic acid]	skin conditioning agent – occlusive
Ricinoleic/Caproic/Caprylic/Capric Triglyceride	Ricinoleic/Caproic/Caprylic/Capric Triglyceride is the mixed triester of glycerin with ricinoleic, caproic, caprylic and capric acids.  [wherein RC(O)- is the residue of ricinoleic, caproic, caprylic, or capric acid]	skin conditioning agent – occlusive

Note: ingredients that were previously reviewed are indicated in [blue](#)

Table 3. Previously Reviewed Components and Related Glyceryl Esters

Component	Conclusion	Reference
Glycerin	safe in cosmetics in the present practices of use and concentration	8
Monoglyceryl Monoesters, including Glyceryl Acetate, Glyceryl Arachidate, Glyceryl Behenate, Glyceryl Caprate, Glyceryl Caprylate, Glyceryl Caprylate/ Caprate, Glyceryl Citrate/Lactate/Linoleate/Oleate, Glyceryl Cocoate, Glyceryl Erucate, Glyceryl Ethylhexanoate, Glyceryl Heptanoate, Glyceryl Hydrogenated Rapeseedate, Glyceryl Hydrogenated Rosinate, Glyceryl Hydrogenated Soyate, Glyceryl Hydroxystearate, Glyceryl Isopalmitate, Glyceryl Isostearate, Glyceryl Isotridecanoate/Stearate/ Adipate, Glyceryl Laurate, Glyceryl Laurate SE, Glyceryl Laurate/ Oleate, Glyceryl Linoleate, Glyceryl Linolenate, Glyceryl Oleate, Glyceryl Oleate SE, Glyceryl Oleate/Elaidate, Glyceryl Oliviate, Glyceryl Palmitate, Glyceryl Palmitate/Stearate, Glyceryl Palmitoleate, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Glyceryl Rosinate, Glyceryl Stearate , Glyceryl Stearate SE, Glyceryl Stearate/Malate, Glyceryl Tallowate, Glyceryl Undecylenate	safe in the present practices of use and concentration	2
Diglycerides, includes: Glyceryl Dilaurate, Glyceryl Diarachidate, Glyceryl Dibehenate, Glyceryl Dierucate, Glyceryl Dihydroxystearate, Glyceryl Diisopalmitate, Glyceryl Diisostearate, Glyceryl Dilinoleate, Glyceryl Dimyristate, Glyceryl Dioleate, Glyceryl Diricinoleate, Glyceryl Dipalmitate, Glyceryl Dipalmitoleate, Glyceryl Distearate	safe in the present practices of use and concentration, provided the content of 1,2-diesters is not high enough to induce epidermal hyperplasia	9
Acetic Acid	safe in the present practices of use and concentration	55
Caprylic/Capric/Coco Glycerides	safe for use as a cosmetic ingredient	56
Carthamus Tinctorius (Safflower) Seed Oil	safe in the present practices of use and concentration	50
Coconut Acid; Cocos Nucifera (Coconut) Oil	safe for use as a cosmetic ingredient	50
Cocoglycerides; Hydrogenated Coco-Glycerides	safe for use as a cosmetic ingredient	56
Elaeis Guineensis (Palm) Oil; Elaeis Guineensis (Palm) Kernel Oil	safe in the present practices of use and concentration	50
Hydroxystearic Acid	safe as a cosmetic ingredient in the present practices of use	57
Isostearic Acid	safe as a cosmetic ingredient in the present practices of use	57
Lauric Acid	safe in the present practices of use and concentration	58
Macadamia Nut Oil	safe in the present practices of use and concentration	50
Mink Oil	safe in the present practices of use and concentration	52
Myristic Acid Glyceryl Dimyristate Glyceryl Isostearate/Dimyristate	safe in the present practices of use and concentration	59
Oleic Acid	safe in the present practices of use and concentration	58
Olive Acid; Olea Europaea (Olive) Fruit Oil	safe in the present practices of use and concentration	50
Palmitic Acid	safe in the present practices of use and concentration	58
Pelargonic Acid	safe in the present practices of use and concentration	60
Rapeseed Acid; Hydrogenated Rapeseed Oil	safe in the present practices of use and concentration	50
Ricinoleic Acid; Ricinus Communis (Castor) Seed Oil; Hydrogenated Castor Oil	safe in the present practices of use and concentration	61
Shea Oleine	safe in cosmetics in the present practices of use and concentration when formulated to be non-sensitizing	62
Simmondsia Chinensis (Jojoba) Seed Oil	safe in the present practices of use and concentration	63
Soy Acid; Hydrogenated Soybean Oil	safe in the present practices of use and concentration	50
Stearic Acid	safe in the present practices of use and concentration	58
Tallow; Tallow Glyceride; Hydrogenated Tallow Glyceride; Tallow Glycerides; Hydrogenated Tallow Glycerides	safe as a cosmetic ingredient in the present practices of use	53

Table 4. Physical and Chemical Properties

	form	molecular weight	melting point (°C)	specific gravity	density	solubility	refractive index	o/w partition coefficient	saponification value	acid value	hydroxyl value
Triheptanoin ³¹	liquid	428.6	-25		0.964 (at 20°C)	water solubility - <0.05 mg/l		8.86			
Tricaprylin ⁴		470.70	10 (stable); -22 (unstable)		0.9540 (at 20°C)	soluble in ethanol, diethyl ether, benzene, chloroform, and ligroin	1.4482 (at 20°C)				
Tripelargonin ⁶⁴		512.76			0.959 (at 20°C)			10.915			
Triundecanoin ⁴	colorless to slightly amber liquid or white to off-white, waxy solid					Soluble in petroleum ether, chloroform, and hot alcohol; insoluble in water			265-290	10 max	25 max
Trilaurin ⁴	needles (obtained from alcohol as solvent)	638.97	36		0.8986 (at 55°C)	insoluble in water; soluble in alcohol, ether, chloroform, and petroleum ether; very soluble in acetone and benzene	1.4404 (at 60°C)		261		
Trimyristin ⁴	polymorphic (crystallized from ethanol and diethyl ether)	768.28	56.5 (stable) 32 (unstable)			soluble in ether, acetone, benzene, and chloroform	1.4428 (at 60°C)				
Tripalmitin ⁴	needles (obtained from ethanol as solvent)	807.35	66 (stable) 44.7 (unstable)		0.8752 (at 70°C)	soluble in ether, benzene, and chloroform	1.4381 (at 80°C)				
Tristearin ⁴		891.51			0.8559 (at 90°C)	soluble in acetone	1.4395 (at 80°C)				
Caprylic/Capric Triglyceride ⁵					0.92-0.96 (25°C/25°C)	soluble in ethanol to ~20% by weight	1.4480- 1.4510	>3 ³⁵	300-360	0.1 max	5.0 max
Triethylhexanoin ²⁵	colorless to pale yellow, transparent oily liquid	470	73.03 (estimated)			water solubility – 1.2 x 10 ⁻⁷ g/l (at 20°C; calculated)		>6.5 ³⁵ 8.98 (calc)			
Triisostearin ⁴	Light yellow, oily substance								185-210	3 max	30 max
Triolein ⁴	Colorless to yellowish oily liquid polymorphic	885.47	-32 ³⁵		0.8988 (at 60°C)	Practically insoluble in water; slightly soluble in alcohol; soluble in chloroform, ether, petroleum ether, and carbon tetrachloride	1.4621 (at 40°C)		192-202	5 max	10 max
Trihydroxystearin ¹	white, finely divided powder	939.49	85-86	1.023 (at 25°C)	8.51						

Table 5. 2017¹³⁻¹⁵ and historical^{1,4,6} frequency and concentration of use of triglycerides according to duration and exposure

	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)		
	Caprylic/Capric Triglyceride				Glyceryl Triacetyl Hydroxystearate				
	2017	2003	2017	2003 ⁶	2017	1998	2017	1998	
Totals*	6000	763	0.0000067-95.6	0.00001-84	20	3	1-19.6	9	
<i>Leave-On</i>	5403	704	0.0000067-95.6	0.00001-84	20	3	1-19.6	9	
<i>Rinse-Off</i>	574	59	0.0000067-89.2	0.002-10	NR	NR	NR	NR	
<i>Diluted for (Bath) Use</i>	23	NR	0.099	7-78	NR	NR	NR	NR	
Eye Area	1063	207	1-83.3	0.008-49	NR	NR	NR	NR	
Incidental Ingestion	585	75	1.2-54	0.002-54	20	2	1-19.6	9	
Incidental Inhalation-Spray	122; 1446 ^a ; 1356 ^b	30; 150 ^a ; 104 ^b	0.019-38.6; 0.00001-28.8 ^a ; 0.0034-1.3 ^b	0.00005-84; 0.0001-19 ^a ; 0.06-48 ^b	NR	1 ^a	NR	NR	
Incidental Inhalation-Powder	77; 1356 ^b ; 25 ^c	11; 104 ^b ; 2 ^c	3.2-16; 0.0034-1.3 ^b ; 0.67-95.6 ^c	0.01-22; 0.06-48 ^b ; 0.8 ^c	NR	NR	NR	NR	
Dermal Contact	5195	672	0.000021-95.6	0.00005-84	NR	NR	NR	NR	
Deodorant (underarm)	6 ^b	1 ^b	not spray: 0.000021-9; spray: 0.09-0.99	0.00005-5 ^b	NR	NR	NR	NR	
Hair - Non-Coloring	161	10	0.0000067-89.2	0.00005-18	NR	1	NR	NR	
Hair-Coloring	22	1	0.00002-4.1	NR	NR	NR	NR	NR	
Nail	17	5	0.08-50	0.2-15	NR	NR	1-19.6	NR	
Mucous Membrane	698	75	0.0001-55.7	0.002-78	20	2	NR	9	
Baby Products	37	5	3.2-52	0.8	NR	NR	NR	NR	
	Glyceryl Triacetyl Ricinoleate				Tribehenin				
	2017	1998	2017	1998	2017	1998	2017	1998	
Totals*	17	32	1-49.2	8	723	42	0.002-15	0.31-6	
Duration of Use									
<i>Leave-On</i>	17	32	1-49.2	8	695	38	0.002-15	0.31-6	
<i>Rinse-Off</i>	NR	NR	NR	NR	28	4	0.002-7	NR	
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR	
Exposure Type									
Eye Area	3	NR	27.1-49.2	NR	95	3	0.04-15	0.32	
Incidental Ingestion	7	31	1-8	8	249	NR	0.01-5.6	0.38	
Incidental Inhalation-Spray	1 ^a	NR	NR	NR	9; 77 ^a ; 53 ^b	4 ^a ; 3 ^b	0.002-8 ^a	3 ^a ; 0.38 ^b	
Incidental Inhalation-Powder	NR	NR	6.3	NR	2; 53 ^b ; 1 ^c	3 ^b	0.015-5.4; 0.002-4.8 ^c	0.38 ^b	
Dermal Contact	10	1	6.3-49.2	NR	409	38	0.002-8	0.32-6	
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	5.1	3-6 ^b	
Hair - Non-Coloring	NR	NR	NR	NR	28	4	0.015-8	NR	
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR	
Nail	NR	NR	NR	NR	4	NR	NR	NR	
Mucous Membrane	7	31	1-8	8	255	NR	0.01-7	0.38	
Baby Products	NR	NR	NR	NR	1	NR	NR	NR	
	Tricaprin ^d				Tricaprylin				
	2017	1998	2017	1998	2017	1998	2017	1998	
Totals*	51	NR	0.75	NR	262	47^c	70	0.0002-12.7	0.5-10
<i>Leave-On</i>	47	NR	0.75	NR	256	47	66	0.0002-11	0.5-10
<i>Rinse-Off</i>	4	NR	0.75	NR	6	NR	4	0.25-12.7	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area	5	NR	NR	NR	111	3	5	2-8	NR
Incidental Ingestion	3	NR	NR	NR	37	11	15	0.035-5	NR
Incidental Inhalation-Spray	6 ^a ; 17 ^b	NR	NR	NR	1; 23 ^a ; 23 ^b	9 ^a ; 23 ^b	10 ^a ; 6 ^b	4.1; 7 ^a	2 ^a ; 2 ^b
Incidental Inhalation-Powder	17 ^b	NR	0.75 ^c	NR	39; 23 ^b ; 23 ^a ; 1 ^c	23 ^b	2; 6 ^b	1.5-2.3; 0.0002-7.5 ^c	5; 2 ^b
Dermal Contact	47	NR	0.75	NR	221	34	51	0.0002-11	0.5-10
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	1	NR	NR	NR	4	NR	3	0.25-7	NR
Hair-Coloring	NR	NR	0.75	NR	NR	2	NR	12.7	NR
Nail	NR	NR	NR	NR	NR	NR	1	NR	NR
Mucous Membrane	3	NR	NR	NR	37	11	15	0.035-5	NR
Baby Products	NR	NR	NR	NR	1	NR	NR	NR	NR

Table 5. 2017¹³⁻¹⁵ and historical^{1,4-6} frequency and concentration of use of triglycerides according to duration and exposure

	# of Uses		Max Conc of Use (%)		# of Uses		Max Conc of Use (%)	
	Trilinolein				Trimyristin			
	2017	1998	2017	1998	2017	1998	2017	1998
Totals*	27	2	0.00048-0.017	NR	27	10	0.12-8	1-2
<i>Leave-On</i>	12	2	0.0048-0.017	NR	27	10	0.12-8	1-2
<i>Rinse-Off</i>	15	NR	0.00048-0.0048	NR	NR	NR	2	NR
<i>Diluted for (Bath) Use</i>	NR	NR	0.00048	NR	NR	NR	NR	NR
Eye Area	NR	NR	NR	NR	3	1	0.2-8	2
Incidental Ingestion	NR	NR	0.0048	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	4 ^a ; 1 ^b	1 ^a	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Powder	1 ^b	NR	0.0048-0.017 ^c	NR	10	5	0.5 ^e	1
Dermal Contact	27	2	0.00048-0.017	NR	27	10	0.12	1-2
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	0.12-8	NR
Hair - Non-Coloring	NR	NR	0.00048	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	15	NR	0.00048-0.0048	NR	NR	NR	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
	Triolein				Tripalmitin			
	2017	1998	2015	1998	2017	1998	2015	1998
Totals*	107	NR	0.00053-0.14	NR	12	1	0.094-19.3	2
<i>Leave-On</i>	92	NR	0.0008-0.14	NR	10	NR	0.094-19.3	NR
<i>Rinse-Off</i>	15	NR	0.00053-0.025	NR	2	1	1	2
<i>Diluted for (Bath) Use</i>	NR	NR	0.00053	NR	NR	NR	NR	NR
Eye Area	3	NR	0.005-14	NR	8	NR	0.094-19.3	NR
Incidental Ingestion	68	NR	0.0008-0.0053	NR	NR	NR	15.6	NR
Incidental Inhalation-Spray	3 ^a ; 1 ^b	NR	NR	NR	1 ^b	NR	NR	NR
Incidental Inhalation-Powder	1 ^b	NR	0.0053-0.025 ^c	NR	NR	NR	0.7 ^e	NR
Dermal Contact	39	NR	0.00053-0.14	NR	12	1	0.094-19.3	2
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	0.00053	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	1	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	83	NR	0.00053-0.0053	NR	1	NR	15.6	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR
	Tristearin				Triundecanoin ^f			
	2017	1998	2015	1998	2017	1998	2015	1998
Totals*	66	46	0.004-24	3	4	NR	1.5	NR
<i>Leave-On</i>	54	42	0.004-24	3	3	NR	NR	NR
<i>Rinse-Off</i>	12	4	NR	NR	1	NR	1.5	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR	NR	NR
Eye Area	9	22	0.004-24	2	NR	NR	NR	NR
Incidental Ingestion	3	4	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	2; 14 ^a ; 14 ^b	2; 3 ^a ; 5 ^b	NR	NR	2 ^a ; 1 ^b	NR	NR	NR
Incidental Inhalation-Powder	14 ^b	5 ^b	NR	NR	1 ^b	NR	NR	NR
Dermal Contact	63	42	0.004-24	0.1-3	4	NR	1.5	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR	NR	NR
Mucous Membrane	12	4	NR	NR	NR	NR	1.5	NR
Baby Products	NR	NR	NR	NR	NR	NR	NR	NR

Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

**at the time of the original safety assessment, concentration of use data were not reported by the FDA.

a concentration range was specified, but not details were provided

^a It is possible these products are sprays, but it is not specified whether the reported uses are sprays..

^b Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories

^c It is possible these products are powders, but it is not specified whether the reported uses are powders

^d as Capric Triglyceride in VCRP

^e as Caprylic Triglyceride in VCRP

^f as Glyceryl Triundecanoate in VCRP

NR – no reported use

Table 6. Frequency¹³ and concentration of use^{14,15} previously unreviewed triglycerides

	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)
	C12-18 Acid Triglyceride		C18-36 Acid Triglyceride		Caprylic/Capric/Lauric Triglyceride	
Totals*	18	0.2-0.33	216	0.64-26.1	4	NR
Duration of Use						
<i>Leave-On</i>	18	0.2-0.33	216	0.64-26.1	4	NR
<i>Rinse-Off</i>	NR	NR	NR	NR	NR	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR
Exposure Type						
Eye Area	2	0.2-0.33	92	0.76-4.5	NR	NR
Incidental Ingestion	14	NR	NR	1.3-26.1	NR	NR
Incidental Inhalation-Spray	1 ^a	NR	3; 1 ^a ; 5 ^b ;	9.2; 11 ^a	2 ^a ; 2 ^b	NR
Incidental Inhalation-Powder	1; 1 ^a	NR	1 ^a	NR	2 ^a	NR
Dermal Contact	4	0.2-0.33	134	0.64-20	3	NR
Deodorant (underarm)	NR	NR	NR	0.64-3.5	NR	NR
Hair - Non-Coloring	NR	NR	3	11	1	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	1	NR	NR	NR
Mucous Membrane	14	NR	NR	1.3-26.1	NR	NR
Baby Products	NR	NR	NR	NR	NR	NR
	Caprylic/Capric/Linoleic Triglyceride		Caprylic/Capric/Myristic/Stearic Triglyceride		Caprylic/Capric/Stearic Triglyceride	
Totals*	NR	0.001-52.1	229	0.015-15.3	22	1-17.7
Duration of Use						
<i>Leave-On</i>	NR	0.001-52.1	217	0.015-15.3	21	1-17.7
<i>Rinse Off</i>	NR	NR	12	0.1-8	1	2
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR
Exposure Type						
Eye Area	NR	NR	29	0.075-15.3	3	1.3-17.7
Incidental Ingestion	NR	NR	7	1.9-8.6	1	NR
Incidental Inhalation-Spray	NR	NR	1; 156 ^a ; 18 ^b	0.1-6 ^a	6; 7 ^a ; 2 ^b	NR
Incidental Inhalation-Powder	NR	0.001-52.1 ^c	156 ^a	0.18-8 ^c	7 ^a	1 ^c
Dermal Contact	NR	0.001-52.1	221	0.015-15.3	18	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	1	0.1-5	3	2
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	NR	NR	12	1.9-8.6	2	NR
Baby Products	NR	NR	NR	NR	NR	NR
	C10-40 Isoalkyl Acid Triglyceride		C10-18 Triglycerides		Glyceryl Tri-Hydrogenated Rosinate	
Totals*	1	NR	93	0.0049-48.4	NR	61
Duration of Use						
<i>Leave-On</i>	1	NR	91	0.0049-48.4	NR	NR
<i>Rinse-Off</i>	NR	NR	1	0.0049-0.25	NR	61
<i>Diluted for (Bath) Use</i>	NR	NR	1	NR	NR	NR
Exposure Type						
Eye Area	NR	NR	23	3.5-43.9	NR	NR
Incidental Ingestion	1	NR	11	0.1-48.4	NR	NR
Incidental Inhalation-Spray	NR	NR	22 ^a ; 22 ^b	1.3 ^a	NR	NR
Incidental Inhalation-Powder	NR	NR	1; 22 ^a ; 1 ^c	0.1-2.7; 0.0049-5 ^c	NR	NR
Dermal Contact	NR	NR	82	0.0049-43.9	NR	61
Deodorant (underarm)	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	0.25	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	1	NR	12	0.1-48.4	NR	NR
Baby Products	NR	NR	1	NR	NR	NR

Table 6. Frequency¹³ and concentration of use^{14,15} previously unreviewed triglycerides

	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)	# of Uses	Max Conc of Use (%)
	Hydrogenated C12-18 Triglycerides		Palmitic/Stearic Triglyceride		Trilinolenin^d	
Totals*	12	1-39.3	6	NR	2	NR
Duration of Use						
<i>Leave-On</i>	10	1-39.3	6	NR	2	NR
<i>Rinse-Off</i>	2	NR	NR	NR	NR	NR
<i>Diluted for (Bath) Use</i>	NR	NR	NR	NR	NR	NR
Exposure Type						
Eye Area	NR	39.3	NR	NR	NR	NR
Incidental Ingestion	NR	NR	NR	NR	NR	NR
Incidental Inhalation-Spray	1 ^a , 5 ^b	NR	2 ^a , 3 ^b	NR	2 ^a	NR
Incidental Inhalation-Powder	1 ^a	NR	2 ^a , 1 ^c	NR	2 ^a	NR
Dermal Contact	12	1-39.3	6	NR	2	NR
Deodorant (underarm)	NR	NR	NR	NR	NR	NR
Hair - Non-Coloring	NR	NR	NR	NR	NR	NR
Hair-Coloring	NR	NR	NR	NR	NR	NR
Nail	NR	NR	NR	NR	NR	NR
Mucous Membrane	1	NR	NR	NR	NR	NR
Baby Products	NR	NR	1	NR	NR	NR

*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^a Not specified whether a spray or a powder, but it is possible the use can be as a spray or a powder, therefore the information is captured in both categories

^b It is possible these products are sprays, but it is not specified whether the reported uses are sprays..

^c It is possible these products are powders, but it is not specified whether the reported uses are powders

^d as Linoleic Acid Triglyceride in VCRP

NR – no reported use

Table 7. Ingredients not reported to be in use¹³⁻¹⁵

Acetic/Linoleic/Palmitic Triglyceride	Glyceryl Tripalmitate/Palm Kernelate/Olivate/Macadamate/Rapeseedate	Triarachidin
C8-12 Acid Triglyceride	Isomerized Safflower Glycerides	Trierucin
Capric/Lauric/Myristic/Oleic Triglyceride	Jobba Oil/Caprylic/Capric Triglyceride Esters	Triheptylundecanoin
Caprylic/Capric/Palmitic/Stearic Triglyceride	Lauric/Palmitic/Oleic Triglyceride	Triisopalmitin
Cod Liver/Mink/Tallow Triglyceride	Oleic/Linoleic Triglyceride	Tripalmitolein
Docosahexenoic/Docosapentenoic/Oleic/Palmitic Triglyceride	Oleic/Palmitic/Lauric/Myristic/Linoleic Triglyceride	Tripelargonin
Glyceryl Stearate Diacetate	Ricinoleic/Caprylic/Caprylic/Capric Triglyceride	Triricinolein

Table 8. Acute Toxicity Studies

Ingredient	Animals	No./Group	Vehicle	Concentration/Dose/Procedure	LD ₅₀ /observations	Reference
DERMAL						
Triheptanoin	rats	5/sex	none	24 h semi-occlusive patch with 2 g/kg	>2 g/kg	31
Tristearin	rats	5/sex	corn oil	24 h semi-occlusive patch with 2 g/kg	>2 g/kg	32
ORAL						
Triheptanoin	NMRI mice	5 males	none	5 g/kg by gavage	>5 g/kg	31
Tripelargonin; Triethylhexanoin	newborn Rhesus (<i>Macaca mulatta</i>) monkeys	5	none	8.4 ml/kg bw by nasogastric tube	Did not affect alertness or activity level; did not induce narcolepsy	29
Triethylhexanoin	rats	not provided	not provided	not specified	>48 g/kg	35
Triisostearin	Swiss mice	5 females	none	2 g/kg by gavage	>2 g/kg	33
Triisostearin	Sprague-Dawley rats	5/sex	none	2 g/kg by gavage	>2 g/kg	33
Triolein	Wistar rats	5/sex	none	2 g/kg by gavage	>2 g/kg	34
MLCT	Wistar rats	5/sex	none	5 g/kg MLCT oil or mixed rapeseed and soybean oils (7:3; control) by gavage	>5 g/kg	35

Abbreviations: MLCT – medium- and long-chain triacylglycerol (length C8 -C24)

Table 9. Short-Term, Subchronic, and Chronic Oral Toxicity Studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose	Procedure	Results	Reference
SHORT-TERM TOXICITY STUDIES							
ANIMAL							
ORAL							
Caprylic/Capric Triglyceride, 33% (v/v)	Han-Wistar rats, 3/sex	28 days (1/sex was dosed for 32 days)	water	0 or 3.12 g/kg	animals were dosed orally (assumed by gavage), 1x/day, with a dose volume of 10 ml/kg	no clinical signs of toxicity were observed; no differences in clinical pathology parameters, cytochrome P450 induction, or gross or microscopic lesions were observed	36
Caprylic/Capric Triglyceride	Han-Wistar rats, 15/sex	28 days	none	undiluted	Animals were dosed daily by gavage (dose vol 0.5 and 2 ml/kg/day) Controls were dosed with 0.5% carboxymethylcellulose/0.1% Tween 80 in water (2 ml/kg/day) Ten animals/sex were killed at the termination of dosing; a recovery group of 5 animals/sex were killed after a subsequent 4-wk non-treatment period	Soft and/or mucoid stools were observed in 12 male and 11 female test animals Absolute and relative thymic weights were decreased in males and females without histological alterations; histopathology revealed increased alveolar histiocytosis with focal interstitial inflammation in lungs in 5/10 test males and 7/10 test females, compared to 1/10 male and 1/10 female controls; all effects were reversible during the recovery period Statistically significant changes noted in clinical chemistry and urinalysis parameters were reversible	37
Caprylic/Capric Triglyceride	Göttingen minipigs; 3/sex	6 wks	none	undiluted; 0.5 or 2 ml/kg/day	Animals were dosed daily by gavage Controls were dosed with 0.5% methylcellulose/0.1% Tween 80 in water (2 ml/kg/day)	<u>0.5 and 2 ml/kg/day</u> : transient tremors, abnormal feces color, and increased triglycerides. <u>2 ml/kg/day</u> : also, reduced motor activity, decreased food intake, respiratory signs (2/6 animals) and increased total and LDL-cholesterol; at necropsy, the lung of 3/6 animals presented abnormal color and/or irregular surface correlated with a chronic bronchioalveolar inflammation (attributed by the researchers to aspiration pneumonia) No changes in organ weights or gross or microscopic lesions were observed, and no toxicologically-relevant changes in hematology or urinalysis parameters were noted	38
Caprylic/Capric Triglyceride	Wistar rats, 10 males/group	30 days	none	10.2 – 20.1 g/kg bw/day	animals were dosed once daily by gavage, in accord with OECD TG 407	NOAEL = ~10 g/kg bw/day reduced food consumption, softened feces, ruffled fur were observed in the high dose group during the first days of the study	39
MLCT	Wistar rats; 20 males/group	6 wks	none	diet containing 7% MLCT or rapeseed oil (control) (equiv to 3.5 g/kg/day)	6-wk dietary study	NOAEL = 3.5 g/kg/day no adverse effects were observed feed consumption, total carcass protein, and serum cholesterol values were statistically significantly increased; total body fat was statistically significantly decreased	28
PARENTERAL							
Tripelargonin/LCT (7/3 wt/wt) emulsion	New Zealand rabbits; 8 male	11 days	none	46.5% of total daily energy	TPN infusions 7 h/day; controls were given isocaloric amounts of a standard food; the animals were killed on day 12	No signs of toxicity; no effect on organ weights or liver lipid concentrations; macroscopic, but not microscopic, changes were noted in the liver	30,40

Table 9. Short-Term, Subchronic, and Chronic Oral Toxicity Studies

Ingredient	Animals/Group	Study Duration	Vehicle	Dose	Procedure	Results	Reference
HUMAN							
MLCT	20 healthy males and females	4 wks		"bread" containing mixed rapeseed and soybean oils (7:3; controls) or MLCT; 42 g oil/day consumed	placebo-controlled double blind study ; hematology and urinalysis were conducted at study initiation and study termination; liver and renal function were measured; body wts and body mass index were measured	no adverse effects	28
SUBCHRONIC TOXICITY STUDIES							
Caprylic/Capric Triglyceride	Wistar rats, 20/sex	90 days	none	1 and 5%	dietary study, in accord with OECD TG 408; changes in organ weights were not measured; microscopic examination was not performed	NOAEL = 5% no signs of systemic toxicity; all animals survived until study termination; no effects on body weight gain, hematology, clinical chemistry, urinalysis, or gross pathology	39
Caprylic/Capric Triglyceride	Beagle dogs, 4/sex	91 days	none	0, 5, 10, and 15%	3-h feeding regimen for the course of the study; dry dog food with beef tallow; animals were observed daily; body weight and feed consumption were measured; hematology, serum chemistry, and urine analysis were performed	NOAEL = 15% No toxicologically-significant clinical signs of toxicity; no significant differences in body wts or feed consumption; no mortality; no test article-related changes in hematology parameters; some changes in clinical chemistry parameters may have been related to the test article; decreased urine volume with increased specific gravity was reported in the mid- and high-dose group	41
CHRONIC TOXICITY STUDIES							
oil consisting of: 64% Triheptanoin 34% diheptanoin 2% monoheptanoin	Wistar rats, 10 males	9 mos	none	control diet with either 30% or 50% substitution of soybean oil with test oil	animals were exposed to <i>ad libitum</i> ; controls were fed AIN-3 diet (lipid source is exclusively soybean oil); body wts were measured; biochemistry analysis (for hepatic and renal function) was performed; the liver, kidneys, and small intestine were examined microscopically	no toxic effects were observed	42

Abbreviations: LCT – long chain triglyceride (length C_{16:0} – C_{18:3}); MLCT – medium- and long-chain triacylglycerol (length C₈ - C₂₄); NOAEL – no-observable adverse effect level; OECD – Organisation for Economic Cooperation and Development; TG – test guideline; TPN – total parenteral nutrition

Table 10. Genotoxicity studies

Test Article	Concentration/Dose	Vehicle	Test System	Procedure	Results	Reference
IN VITRO						
Tristearin	5000 µg/plate	95% ethanol	<i>S. typhimurium</i> TA1535, TA1537, TA98, TA100	Ames test, in accord with OECD TG 471, with and without metabolic activation; solvent and appropriate positive controls were used	negative	32
Caprylic/Capric Triglyceride	not stated	not stated	not stated	Ames test	negative	35
Triethylhexanoin	50-5000 µg/plate	DMSO	<i>S. typhimurium</i> TA1535, TA1537, TA98, TA100, TA102	Ames test, in accord with OECD TG 471, with and without metabolic activation; solvent and appropriate positive controls were used	negative	25
Triethylhexanoin	7.5-4000 µg/ml	ethanol	human lymphocytes	mammalian chromosomal aberration assay, in accord with OECD TG 473; with and without metabolic activation; solvent and appropriate positive controls were tested	negative	35
Triisononanoïn	50-5000 µg/plate	acetone	<i>S. typhimurium</i> TA1535, TA1537, TA98, TA100 <i>Escherichia coli</i> WP2uvrA	Ames test, with and without metabolic activation; solvent and appropriate positive controls were used	negative	44
Triisononanoïn	10-320 µg/ml	acetone	cultured peripheral human lymphocytes	chromosomal aberration assay, with and without metabolic activation; solvent and appropriate positive controls were used	negative	44
Triisononanoïn	5-80 µg/ml	acetone	mouse lymphoma L5178Y cells	mammalian cell gene mutation assay, with and without metabolic activation; solvent and appropriate positive controls were used	negative	44
lipid emulsion comprised of Caprylic/Capric Triglyceride, soybean oil, olive oil, and fish oil	not provided	not provided	<i>S. typhimurium</i>	Ames test (details not provided)	negative	27
lipid emulsion comprised of Caprylic/Capric Triglyceride, soybean oil, olive oil, and fish oil	not provided	not provided	human lymphocytes	chromosomal aberration assay (details not provided)	negative	27
lipid emulsion comprised of Caprylic/Capric Triglyceride, soybean oil, olive oil, and fish oil	not provided	not provided	V79 cells	HPRT gene mutation assay (details not provided)	negative	27
MLCT	313-5000 µg/plate	sodium phosphate buffer	<i>S. typhimurium</i> TA1535, TA1537, TA98, TA100 <i>E. coli</i> WP2uvrA	Ames test, with and without metabolic activation; solvent and appropriate positive controls were used	negative	28
IN VIVO						
lipid emulsion comprised of Caprylic/Capric Triglyceride, soybean oil, olive oil, and fish oil	not provided	not provided	rats	bone marrow cytogenic study (details not provided)	negative	27

Abbreviations: DMSO – dimethyl sulfoxide; HPRT - hypoxanthine phosphoribosyl transferase; MLCT – medium- and long-chain triacylglycerol (length C8 -C24); OECD – Organisation for Economic Cooperation and Development; TG – test guideline

Table 11. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
IN VITRO					
Triisononanoïn	undiluted, 10 µl	EpiSkin™ reconstructed human epidermis model	EPISKIN™ in vitro test, in accord with OECD TG 439; appropriate negative and positive controls were used	predicted to be not irritating	44
ANIMAL					
Triheptanoïn	undiluted, 0.5 ml	White Russian rabbits, 6 male	4- h semi-occlusive patches were applied to a 6 cm ² area performed in accord with OECD TG 404	mean erythema score – 2.22/4; mean edema score – 1.94/4 30-60 min: very slight to well-defined erythema in all animals 24-72 h: moderate to severe erythema and severe edema with brown discolorations and dryness, with sanguineous lacerations and scaling in 1 animal 72 h: 1 animal showed moderate redness of the skin, with dry skin and severe extensive subcutaneous hemorrhage 6 days: scaling was observed in all animals 10-14 days: all animals were normal	31
Triheptanoïn	undiluted, 0.5 ml	NZW rabbits, 3 males	4- h semi-occlusive patches were applied in accord with OECD TG 404	1 h: very slight and slight erythema in 1 and 2 animals, respectively. 24 h: very slight edema in one of the latter animals very slight and slight erythema in 2 and 1 animals, respectively. 48 h: very slight edema in the latter. 48 and 72 h: very slight erythema in 2 animals, with very slight edema in one	31
Triheptanoïn	100% for induction and challenge	female Dunkin Hartley guinea pigs, 20 test animals and 10 controls	Buehler test using occlusive patches at induction and challenge	not a sensitizer	31
Tristearin	undiluted, 0.5 ml	NZW rabbits, 3 males	4- h semi-occlusive patches were applied to a 6 cm ² area in accord with OECD TG 404	not irritating no erythema or edema were observed	32
Tristearin	50% in petrolatum for induction and challenge	Dunkin Hartley guinea pigs, 20 test animals and 10 controls	Buehler test using occlusive patches at induction and challenge	not a sensitizer	32
Caprylic/Capric Triglyceride	undiluted, 0.5 ml	NZW rabbits, 6	4-h semi-occlusive patches	not irritating no erythema or edema were observed	39
C8-C12 Acid Triglycerides	undiluted, 0.5 ml	albino rabbits, 3	24-, 48-, and 72-h semi-occlusive application using pieces of soaked "Molton" in accord with OECD TG 404; the application site was 2.5 cm x 2.5 cm	not irritating no erythema or edema were observed	39
Triisononanoïn	25 and 50% in acetone/oil (4:1 v/v), and undiluted	CBA mice, 4 females	LLNA in accord with OECD TG 429	negative at 25 and 50% (SI = 2.1 and 2.16, respectively) positive at 100% (SI = 4.27); may cause sensitization EC ₃ = 70%	44
Triisostearin	concentration and vehicle not stated	NZW rabbits, 3 males	4- h semi-occlusive patches were applied to a 6 cm ² area in accord with OECD TG 404	1 and 24 h: well-defined erythema observed in 3/3 animals 48 h: slight erythema persisted in 2/3 animals 72 h: erythema cleared completely no edema was observed in any animal at any time point	35

Table 11. Dermal irritation and sensitization studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
HUMAN					
facial oil containing 95.51% Caprylic/Capric Triglyceride	applied neat	17 subjects	SIOPT; 24 h patch	not irritating; PII = 0	45
facial oil containing 95.51% Caprylic/Capric Triglyceride		26 subjects	modified maximization test procedure; 5 occlusive patches (2 cm x 2 cm) were applied for 48-72 h; the test sites were pretreated with 0.25% SLS one day prior to patching Challenge was conducted following a 14-day non-treatment period; an occlusive patch with 5.0% SLS was applied for 1 h, followed by application of a test patch for 48 h; controls were patched with a sham patch following SLS pretreatment	not a sensitizer	46
moisturizer containing 6% Tribehenin	applied neat; 0.01 g (pink solid paste)	102 subjects	HRIPT; 24-h occlusive patches (2 cm x 2 cm) were applied to the upper back 3 x/wk for 3 wks; challenge was performed following an 8-19 day non-treatment period with a 24-h occlusive patch to a previously untreated site	no adverse events were reported not a sensitizer	47
mixture containing 20% Tribehenin	0.2 g	52 subjects	HRIPT; 24-h occlusive patches (1 in x 1 in) were applied to the upper back 3 x/wk for 3 wks; challenge was performed following a 2 wk non-treatment period with a 24-h occlusive patch to a previously untreated site	8 subjects had a response on a least one day of induction, ranging from barely perceptible (+) to moderate (score of 2; 1 occurrence); at challenge, one subject had a mild reaction at the 72 h reading and a barely perceptible reaction with dryness at a 96-h follow-up evaluation the researchers stated that none of these responses were considered clinically significant, and concluded there was no clinically significant potential for dermal irritation or sensitization	48
Triolein	not stated	human subjects; number not stated	chamber test; details not provided	not a sensitizer	35

Abbreviations: HRIPT – human repeated insult patch test; LLNA – local lymph node assay; NZW – New Zealand White; OECD – Organisation for Economic Cooperation and Development; PII – primary irritation index; SI – stimulation index; SIOPT - single insult occlusive patch test; SLS – sodium lauryl sulfate; TG – test guideline

Table 12. Ocular irritation studies

Test Article	Concentration/Dose	Test Population	Procedure	Results	Reference
IN VITRO					
Triisononanoil	undiluted, 30 µl	HCE model	In vitro eye irritation test using the SkinEthic™ reconstructed model	predicted to be non-irritating	44
ANIMAL					
Triheptanoil	undiluted, 0.1 ml	rabbits, 3 males	24 h instillation into one eye	non-irritating	31
Tristearin	undiluted, 0.1 ml	rabbits, 3 males	24 h instillation into one eye in accord with OECD TG 405	non-irritating any effects observed were resolved by day 6	32
Caprylic/Capric Triglyceride	undiluted, 0.1 ml	NZW rabbits, 6	single instillation into one eye; 72-h observation period	non-irritating	39
C8-C12 Acid Triglyceride	undiluted, 0.05 ml	albino rabbits, 3	6 instillations were made on 6 consecutive days; animals were observed for 10 days	non-irritating	39
Triisostearin	concentration and vehicle not stated	NZW rabbits, 3 males	24 h instillation into one eye in accord with OECD TG 405	non-irritating any effects observed were resolved within 48 h	33

Abbreviations: HCE - Human Corneal Epithelium; NZW - New Zealand White; OECD – Organisation for Economic Cooperation and Development; TG – test guideline

REFERENCES

1. Andersen FA (ed). Final Report on the Safety Assessment of Trihydroxystearin. *Int J Toxicol*. 2000;19(Suppl 1):89-94.
2. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, and Gill LJ. 2015. Safety Assessment of Monoglyceryl Monoesters as Used in Cosmetics. Available from CIR: <http://www.cir-safety.org/ingredients>.
3. Elder RL (ed). Final report on the safety assessment of glyceryl stearate and glyceryl stearate/SE. *J Am Coll Toxicol*. 1982;1(4):169-192. <http://www.cir-safety.org/ingredients>.
4. Andersen FA (ed). Final Report on the Safety Assessment of Trilaurin, Triarachidin, Tribehenin, Tricaprin, Tricaprylin, Trierucin, Triheptanoin, Triheptylundecanoin, Triisononanoin, Triisopalmitin, Triisostearin, Trilinolein, Trimyrustin, Trioctanoin, Triolein, Tripalmitin, Tripalmitolein, Triricinolein, Tristearin, Triundecanoin, Glyceryl Triacetyl Hydroxystearate, Glyceryl Triacetyl Ricinoleate, and Glyceryl Stearate Diacetate. *Int J Toxicol*. 2001;20(Suppl 4):61-94.
5. Elder RL (ed). Final Report on the Safety Assessment for Caprylic/Capric Triglyceride. *J Environ Pathol Toxicol*. 1980;4(4):105-120.
6. Andersen FA (ed). Annual Review of Cosmetic Ingredients Safety Assessments - 2001/2002: Caprylic/Capric Triglyceride. *Int J Toxicol*. 2003;22(Suppl 1):4-6.
7. Nikitakis J and Lange B. wINCI: International Cosmetic Ingredient Dictionary and Handbook. <http://webdictionary.personalcarecouncil.org/jsp/Home.jsp>. Washington, DC. Last Updated 2017. Date Accessed 7-25-2017.
8. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, and Gill LJ. Safety assessment of glycerin as used in cosmetics. 2015. <http://www.cir-safety.org/ingredients>. Date Accessed 8-23-2015. Available on the CIR website.
9. Andersen FA (ed). Amended Final Report on the Safety Assessment of Glyceryl Dilaurate, Glyceryl Diarachidate, Glyceryl Dibehenate, Glyceryl Dierucate, Glyceryl Dihydroxystearate, Glyceryl Diisopalmitate, Glyceryl Diisostearate, Glyceryl Dilinoleate, Glyceryl Dimyristate, Glyceryl Dioleate, Glyceryl Diricinoleate, Glyceryl Dipalmitate, Glyceryl Dipalmitoleate, Glyceryl Distearate, Glyceryl Palmitate Lactate, Glyceryl Stearate Citrate, Glyceryl Stearate Lactate, and Glyceryl Stearate Succinate. *Int J Toxicol*. 2007;26(Suppl 3):1-30.
10. European Chemicals Agency (ECHA). European Chemicals Agency (ECHA) Information on Chemicals. <https://echa.europa.eu/information-on-chemicals>. Last Updated 2017. Date Accessed 2-23-2017.
11. Lonza, Inc. Notification of the GRAS Determination of Medium Chain Triglycerides When Added Directly to Human Food. <https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm337464.pdf>. Last Updated 2012. Date Accessed 3-14-2017.
12. Burdock Group. Dossier in Support of the Generally Recognized as Safe (GRAS) Status of Medium- and Long-Chain Triacylglycerol (MLCT)-Oil as a Food Ingredient. <https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/UCM269108>. Last Updated 2006. Date Accessed 2-22-2017.
13. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. *FDA Database*. 2017.
14. Personal Care Products Council. 6-15-2017. Updated Concentration of Use by FDA Product Category: Triglycerides. Unpublished data submitted by Personal Care Products Council on June 15, 2017.
15. Personal Care Products Council. 7-6-2017. Concentration of Use by FDA Product Category: Additional Triglycerides. Unpublished data submitted by Personal Care Products Council on July 6, 2017.
16. U.S. Food and Drug Administration (FDA) Center for Food Safety & Applied Nutrition (CFSAN). Voluntary Cosmetic Registration Program - Frequency of Use of Cosmetic Ingredients. College Park, MD, 2017. Obtained under the Freedom of Information Act from CFSAN; requested as "Frequency of Use Data" January 2017; received February 2017.
17. Johnsen MA. The influence of particle size. *Spray Technol Marketing*. 2004;14(11):24-27.

18. Rothe H. Special Aspects of Cosmetic Spray Evaluation. 9-26-2011. Unpublished data presented at the 26 September CIR Expert Panel meeting. Washington, D.C.
19. Rothe H, Fautz R, Gerber E, Neumann L, Rettinger K, Schuh W, and Gronewold C. Special aspects of cosmetic spray safety evaluations: Principles on inhalation risk assessment. *Toxicol Lett.* 2011;205(2):97-104.
20. Bremmer HJ, Prud'homme de Lodder LCH, and Engelen JGM. Cosmetics Fact Sheet: To assess the risks for the consumer; Updated version for ConsExpo 4. 2006. Report No. RIVM 320104001/2006. pp. 1-77.
21. CIR Science and Support Committee of the Personal Care Products Council (CIR SSC). 11-3-2015. Cosmetic Powder Exposure.
22. Aylott RI, Byrne GA, Middleton, J, and Roberts ME. Normal use levels of respirable cosmetic talc: preliminary study. *Int J Cosmet Sci.* 1979;1(3):177-186. PM:19467066.
23. Russell RS, Merz RD, Sherman WT, and Sivertson JN. The determination of respirable particles in talcum powder. *Food Cosmet Toxicol.* 1979;17(2):117-122. PM:478394.
24. European Commission. CosIng database; following Cosmetic Regulation No. 1223/2009. <http://ec.europa.eu/growth/tools-databases/cosing/>. Last Updated 2016. Date Accessed 3-15-2017.
25. National Industrial Chemicals Notification and Assessment Scheme (NICNAS). Full public report: Hexanoic acid, 2-ethyl,1,2,3-propanetriyl ester (Triethylhexanoin). https://www.nicnas.gov.au/_data/assets/word_doc/0019/6670/EX138FR.docx. Last Updated 2017. Date Accessed 2-23-2017.
26. U.S. Food and Drug Administration (FDA). Agency Response Letter GRAS Notice No. GRN 000217. <https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm153864.htm>. Last Updated 2007. Date Accessed 3-14-2017.
27. U.S. Food and Drug Administration (FDA). Labelling information for NDA 207648; Smoflipid. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207648lbl.pdf. Last Updated 2016. Date Accessed 3-13-2017.
28. Matulka RA, Noguchi O, and Nosaka N. Safety evaluation of a medium- and long-chain triacylglycerol oil produced from medium-chain triacylglycerols and edible vegetable oil. *Food Chem Toxicol.* 2006;44(9):1530-1538.
29. Tetrick MA, Greer FR, and Benevenga NJ. Blood D-(-)-3-hydroxybutyrate concentrations after oral administration of trioctanoin, trionanoin, or tridecanoin to newborn Rhesus monkeys (*Macaca mulatta*). *Comparative Medicine.* 2010;60(6):486-490.
30. Linseisen J and Wolfram G. Odd-numbered medium-chain triglycerides (trionanoin) in total parenteral nutrition: effects on parameters of fat metabolism in rabbits. *JPEN J Parenter. Enteral Nutr.* 1993;17(6):522-528. PM:8301805.
31. European Chemicals Agency (ECHA). Propane-1,2,3-triyl trisheptanoate (CAS No. 620-67-7; Triheptanoin). <https://echa.europa.eu/registration-dossier/-/registered-dossier/13795>. Last Updated 2016. Date Accessed 3-13-2017.
32. European Chemicals Agency (ECHA). Glycerol tristearate (CAS No. 555-43-1; Tristearin). <https://echa.europa.eu/registration-dossier/-/registered-dossier/12757>. Last Updated 2016. Date Accessed 3-13-2017.
33. European Chemicals Agency (ECHA). 1,2,3-Propanetriyl Triisooctadecanoate (CAS No. 26942-95-0; Triisostearin). <https://echa.europa.eu/registration-dossier/-/registered-dossier/16104>. Last Updated 1-30-2016. Date Accessed 2-23-2017.
34. European Chemicals Agency (ECHA). 1,2,3-Propanetriyl trioleate (CAS No. 122-32-7; Triolein). <https://echa.europa.eu/registration-dossier/-/registered-dossier/5426>. Last Updated 2017. Date Accessed 3-13-2017.
35. Organisation for Economic Cooperation and Development (OECD). SIDS Initial Assessment Profile: Glycerides. <http://webnet.oecd.org/hpv/ui/handler.axd?id=f29255ef-74da-4be5-8c43-6c2bbe6adf5e>. Last Updated 2014. Date Accessed 2-23-2017.
36. Healing G, Cotton P, Hargreaves A, Finney R, Schramm C, Garner C, Burdett L, Sulemann T, Pivette P, Harris J, and Kirk S. Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl- α -cyclodextrin causes renal toxicity. *Journal of applied toxicology : JAT.* 2016;36(1):140-150.
37. Sellers RS, Antman M, Phillips J, Khan KN, and Furst SM. Effects of Miglyol 812 on rats after 4 weeks of gavage as compared with methylcellulose/tween 80. *Drug Chem Toxicol.* 2005;28(4):423-432. PM:16298873.

38. Le Bars G, Dion S, Gauthier B, Mhedhbi S, Pohlmeier-Esch G, Comby P, Vivian N, and Ruty B. Oral toxicity of Miglyol 812[®] in the Gottingen[®] minipig. *Regul Toxicol Pharmacol*. 2015;73(3):930-937. PM:26408152.
39. European Chemicals Agency (ECHA). Glycerides, mixed decanoyl and octanoyl (CAS No. 73998-61-5; Caprylic/Capric Triglyceride). <https://echa.europa.eu/registration-dossier/-/registered-dossier/16019>. Last Updated 12-17-2016. Date Accessed 2-23-2017.
40. Linseisen J and Wolfram G. Organ changes after intravenous trionanoin administration in rabbits. *Ann Nutr Metab*. 1993;37(6):328-334. PM:8109892.
41. Matulka RA, Thompson L, and Burdock GA. Lack of toxicity of medium chain triglycerides (MCT) in canines during a 90-day feeding study. *Food Chem Toxicol*. 2009;47:35-39.
42. Ataíde T da R, de Oliveira SL, da Silva FM, Vitorino Filha LGC, Tavares MC, and Sant'Ana AEG. Toxicological analysis of the chronic consumption of diheptanoin and triheptanoin in rats. *International Journal of Food Science and Technology*. 2009;44(3):484-492.
43. Christ SA, Read EJ, Stober JA, and Smith MK. Developmental effects of trichloroacetonitrile administered in corn oil to pregnant Long-Evans rats. *Journal of toxicology and environmental health*. 1996;47(3):233-247.
44. European Chemicals Agency (ECHA). Propane-1,2,3-triyl 3,5,5-trimethylhexanoate (CAS No. 56554-53-1; Triisononanoin). <https://echa.europa.eu/registration-dossier/-/registered-dossier/13674>. Last Updated 2015. Date Accessed 3-13-2017.
45. Anonymous. 2015. Clinical evaluation report: Human patch test (facial oil containing 95.51% Caprylic/Capric Triglyceride). Unpublished data submitted by Personal Care Products Council on July 6, 2017.
46. Product Investigations Inc. 2015. Determination of the sensitizing propensities of facial oil (containing 95.51% Caprylic/Capric Triglyceride) on human skin. Unpublished data submitted by Personal Care Products Council on July 6, 2017.
47. TKL Research Inc. 2000. Human repeated insult patch study: Moisturizer with 6% Tribehenin. Unpublished data submitted by Personal Care Products Council on May 18, 2017.
48. Consumer Product Testing Co. 2000. Repeated insult patch test protocol of a material containing 20% Tribehenin. Experiment reference number: C99-1266.03. Unpublished data submitted by Personal Care Products Council on May 17, 2017.
49. KGL Inc. 2015. Photocontact allergenicity potential of a facial oil containing 95.51% Caprylic/Capric Triglyceride. Unpublished data submitted by Personal Care Products Council on July 6, 2017.
50. Burnett CL, Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final Report on the Safety Assessment of Plant-Derived Fatty Acid Oils as Used in Cosmetics. 2011. Available from CIR: <http://www.cir-safety.org/ingredients>.
51. Ilievska B, Loftsson T, Hjalmarsdottir MA, and Asgrimsdottir GM. Topical formulation comprising fatty acid extract from cod liver oil: Development, evaluation, and stability studies. *Mar Drugs*. 2016;14(6):105-116. www.mdpi.com/1660-3397/14/6/105/pdf.
52. Andersen FA (ed). Final Amended Report on the Safety Assessment of Mink Oil. *Int J Toxicol*. 2005;24(Suppl 3):57-64.
53. Elder RL (ed). Final Report on the Safety Assessment of Tallow, Tallow Glyceride, Tallow Glycerides, Hydrogenated Tallow Glyceride, and Hydrogenated Tallow Glycerides. *J Am Coll Toxicol*. 1990;9(2):153-164.
54. Becker L, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final Report on the Safety Assessment of Simmondsia Chinensis (Jojoba) Seed Oil, Simmondsia Chinensis (Jojoba) Seed Wax, Hydrogenated Jojoba Oil, Hydrolyzed Jojoba Esters, Isomerized Jojoba oil, Jojoba Esters, Simmondsia Chinensis (Jojoba) Butter, Jojoba Alcohol, and Synthetic Jojoba Oil. 2008. Available from CIR: <http://www.cir-safety.org/ingredients>
55. Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final report of the Cosmetic Ingredient Review Expert Panel on the safety assessment of methyl acetate. *Int J Toxicol*. 2012;31(Suppl 1):112S-136S. <http://www.cir-safety.org/ingredients>.
56. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final report on the safety assessment of *Cocos nucifera* (coconut) oil and related ingredients. *Int J Toxicol*. 2011;30(Suppl 1):5S-16S. <http://www.cir-safety.org/ingredients>.

57. Elder RL (ed). Final report on the safety assessment of isostearic acid. *J Am Coll Toxicol*. 1983;2(7):61-74. <http://www.cir-safety.org/ingredients>.
58. Elder RL (ed). Final report on the safety assessment of oleic acid, lauric acid, palmitic acid, myristic acid, and stearic acid. *J Am Coll Toxicol*. 1987;6(3):321-401. <http://www.cir-safety.org/ingredients>.
59. Becker L, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final Report of the Amended Safety Assessment of Myristic Acid and Its Salts and Esters as Used in Cosmetics. *Int J Toxicol*. 2010;29(Suppl 3):162S-186S.
60. Johnson W Jr, Heldreth BA, Bergfeld WF, Belsito DV, Klaassen CD, Hill RA, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, and Andersen FA. Final Report of the Cosmetic Ingredient Review Expert Panel on the Safety Assessment of Pelargonic Acid (Nonanoic Acid) and Nonanoate Esters. *Int J Toxicol*. 2011;30(Suppl 3):228S-269S.
61. Andersen FA (ed). Final Report on the Safety Assessment of Ricinus Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glycerol Ricinoleate, Glycerol Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, and Octyldodecyl Ricinoleate. *Int J Toxicol*. 2007;26(Suppl 3):31-77. <http://www.cir-safety.org/ingredients>.
62. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, and Heldreth BA. Safety Assessment of Butyrospermum parkii (Shea)-Derived Ingredients as Used in Cosmetics. 2017. Available from CIR (<https://www.cir-safety.org/ingredients>).
63. Johnson W Jr. 2008. Safety Assessment of Simmondsia Chinensis (Jojoba) Seed Oil, Simmondsia Chinensis (Jojoba) Seed Wax, Hydrogenated Jojoba Oil, Hydrolyzed Jojoba Esters, Isomerized Jojoba Oil, Jojoba Esters, Simmondsia Chinensis (Jojoba) Butter, Jojoba Alcohol, and Synthetic Jojoba Oil. Available from CIR: <http://www.cir-safety.org/ingredients>.
64. Advanced Chemistry Development (ACD/Labs) Software V11.02. 2017.